

References

- Aguirre N, Ballaz S, Lasheras B, Del Rio J (1998a) MDMA ('Ecstasy') enhances 5HT_{1A} receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. *Eur J Pharmacol* 346: 181-8, http://www.maps.org/publications/1998_aguirre_1.pdf
- Aguirre N, Barrionuevo M, Lasheras B, Del Rio J (1998b) The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. *J Pharmacol Exp Ther* 286: 1159-65, http://www.maps.org/publications/1998_aguirre_2.pdf
- Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B (1999) Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. *Neuroreport* 10: 3675-80, http://www.maps.org/publications/1999_aguirre_1.pdf
- Ajaelo I, Koenig K, Snoey E (1998) Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. *Acad Emerg Med* 5: 839-40, http://www.maps.org/publications/1998_ajaelo_1.pdf
- Alciati A, Scaramelli B, Fusi A, Butteri E, Cattaneo ML, Mellado C (1999) Three cases of delirium after "ecstasy" ingestion. *J Psychoactive Drugs* 31: 167-70, http://www.maps.org/publications/1999_alciati_1.pdf
- Alexander GE, Furey ML, Grady CL, Pietrini P, Brady DR, Mentis MJ, Schapiro MB (1997) Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. *Am J Psychiatry* 154: 165-72,
- Ali SF, Newport GD, Holson RR, Slikker W, Jr., Bowyer JF (1994) Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. *Brain Res* 658: 33-8,
- Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR, Paule MG, Slikker W, Jr. (1993) Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. *Neurotoxicol Teratol* 15: 91-6, http://www.maps.org/publications/1993_ali_1.pdf
- Allen RP, McCann UD, Ricaurte GA (1993) Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. *Sleep* 16: 560-4, http://www.maps.org/publications/1993_allen_1.pdf
- Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. *NIDA Res Monogr* 22: 8-15, http://www.maps.org/publications/1978_anderson_1.pdf
- Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, Rodes J (1998) Ecstasy: a common cause of severe acute hepatotoxicity. *J Hepatol* 29: 394-7, http://www.maps.org/publications/1998_andreu_1.pdf
- Angrist B (1994) Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS (eds) *Amphetamine and its analogs: psychopharmacology, toxicology, and abuse*. Academic Press, San Diego, CA, pp 387-414,
- anonymous (1996) Walking on the moon. *Lancet* 347: 207,
- Axt KJ, Mamounas LA, Molliver ME (1994) Structural features of amphetamine neurotoxicity in the brain. In: Cho AK, Segal DS (eds) *Amphetamine and its analogs: psychopharmacology, toxicology, and abuse*. Academic Press, San Diego, CA, pp 315-367, http://www.maps.org/publications/1994_axt_1.pdf
- Ayus JC, Arieff AI (1996) Brain damage and postoperative hyponatremia: the role of gender [see comments]. *Neurology* 46: 323-8,
- Azmitia EC (1999) Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. *Neuropsychopharmacology* 21: 33S-45S,
- Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills. *Jama* 284: 2190, http://www.maps.org/publications/2000_baggott_1.pdf
- Baggott M, Mendelson J, Jones R (1999) More about parkinsonism after taking ecstasy. *N Engl J Med* 341: 1400-1, http://www.maps.org/publications/1999_baggott_1.pdf

- Bai F, Lau SS, Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of alpha-methyl dopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. *Chem Res Toxicol* 12: 1150-7, http://www.maps.org/publications/1999_bai_1.pdf
- Bango J, Fadon P, Mata F, Rubio G, Santo-Domingo J (1998) [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports]. *Actas Luso Esp Neurol Psiquiatr Cienc Afines* 26: 260-3,
- Bartzokis G, Beckson M, Hance DB, Lu PH, Foster JA, Mintz J, Ling W, Bridge P (1999) Magnetic resonance imaging evidence of "silent" cerebrovascular toxicity in cocaine dependence. *Biol Psychiatry* 45: 1203-11,
- Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988a) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. *Eur J Pharmacol* 149: 159-63, http://www.maps.org/publications/1988_battaglia_1.pdf
- Battaglia G, De Souza EB (1989) Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. *NIDA Res Monogr* 94: 240-58, http://www.maps.org/publications/1989_battaglia_1.pdf
- Battaglia G, Yeh SY, De Souza EB (1988b) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. *Pharmacol Biochem Behav* 29: 269-74, http://www.maps.org/publications/1988_battaglia_2.pdf
- Beardsley PM, Balster RL, Harris LS (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. *Drug Alcohol Depend* 18: 149-57, http://www.maps.org/publications/1986_beardsley_1.pdf
- Beatty WW, Katzung VM, Moreland VJ, Nixon SJ (1995) Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. *Drug Alcohol Depend* 37: 247-53,
- Beck JR, M. (1994) *In Pursuit of Ecstasy: The MDMA Experience*, Trade Paperback edn. SUNY Press, SUNY Press,
- Behan WM, Madigan M, Clark BJ, Goldberg J, McLellan DR (2000) Muscle changes in the neuroleptic malignant syndrome. *J Clin Pathol* 53: 223-7, http://www.maps.org/publications/2000_behan_1.pdf
- Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E (2000) Ecstasy-induced toxicity in rat liver. *Liver* 20: 8-15, http://www.maps.org/publications/2000_beitia_1.pdf
- Bendotti C, Baldessari S, Pende M, Tarizzo G, Miari A, Presti ML, Mennini T, Samanin R (1994) Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? *Brain Res Bull* 34: 389-94,
- Berger UV, Grzanna R, Molliver ME (1992a) The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin. *Brain Res* 578: 177-85,
- Berger UV, Gu XF, Azmitia EC (1992b) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. *Eur J Pharmacol* 215: 153-60, http://www.maps.org/publications/1992_berger_1.pdf
- Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. *J Neurochem* 73: 1127-37,
- Bertram M, Egelhoff T, Schwarz S, Schwab S (1999) Toxic leukoencephalopathy following "ecstasy" ingestion. *J Neurol* 246: 617-8, http://www.maps.org/publications/1999_bertram_1.pdf
- Bilsky EJ, Hubbell CL, Delconte JD, Reid LD (1991) MDMA produces a conditioned place preference and elicits ejaculation in male rats: a modulatory role for the endogenous opioids. *Pharmacol Biochem Behav* 40: 443-7, http://www.maps.org/publications/1991_bilsky_1.pdf
- Bilsky EJ, Hui YZ, Hubbell CL, Reid LD (1990) Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. *Pharmacol Biochem Behav* 37: 633-8, http://www.maps.org/publications/1990_bilsky_1.pdf
- Bilsky EJ, Montegut MJ, Nichols ML, Reid LD (1998) CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. *Pharmacol Biochem Behav* 59: 215-20, http://www.maps.org/publications/1998_bilsky_1.pdf
- Bilsky EJ, Reid LD (1991) MDL72222, a serotonin 5HT₃ receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. *Pharmacol Biochem Behav* 39: 509-12, http://www.maps.org/publications/1991_bilsky_2.pdf

- Bingham C, Beaman M, Nicholls AJ, Anthony PP (1998) Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). *Nephrol Dial Transplant* 13: 2654-5, http://www.maps.org/publications/1998_bingham_1.pdf
- Bitsch A, Thiel A, Rieckmann P, Prange H (1996) Acute inflammatory CNS disease after MDMA ('ecstasy'). *Eur Neurol* 36: 328-9, http://www.maps.org/publications/1996_bitsch_1.pdf
- Bizot J, Le Bihan C, Puech AJ, Hamon M, Thiebot M (1999) Serotonin and tolerance to delay of reward in rats. *Psychopharmacology (Berl)* 146: 400-12,
- Bjorklund A, Stenevi U (1979) Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. *Physiol Rev* 59: 62-100,
- Bohn M, Bohn G, Blaschke G (1993) Synthesis markers in illegally manufactured 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine. *Int J Legal Med* 106: 19-23, http://www.maps.org/publications/1993_bohn_1.pdf
- Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. *Neurology* 51: 1532-7, http://www.maps.org/publications/1998_bolla_1.pdf
- Bolla KI, Rothman R, Cadet JL (1999) Dose-related neurobehavioral effects of chronic cocaine use. *J Neuropsychiatry Clin Neurosci* 11: 361-9,
- Borg GJ (1999) More about parkinsonism after taking ecstasy. *N Engl J Med* 341: 1400; discussion 1401, http://www.maps.org/publications/1999_borg_1.pdf
- Bowyer JF, Gough B, Slikker W, Jr., Lipe GW, Newport GD, Holson RR (1993) Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. *Pharmacol Biochem Behav* 44: 87-98,
- Box SA, Prescott LF, Freestone S (1997) Hyponatraemia at a rave. *Postgrad Med J* 73: 53-4, http://www.maps.org/publications/1997_box_1.pdf
- Boys A, Marsden J, Griffiths P, Fountain J, Stillwell G, Strang J (1999) Substance use among young people: the relationship between perceived functions and intentions. *Addiction* 94: 1043-50, http://www.maps.org/publications/1999_boys_1.pdf
- Boys ALSNK (1997) Polydrug use at raves by a Western Australian sample. *Drug & Alcohol Review* 16: 227-234,
- Brady JF, Di Stefano EW, Cho AK (1986) Spectral and inhibitory interactions of (+/-)-3,4-methylenedioxyamphetamine (MDA) and (+/-)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. *Life Sci* 39: 1457-64, http://www.maps.org/publications/1986_brady_1.pdf
- Brauer RB, Heidecke CD, Nathrath W, Beckurts KT, Vorwald P, Zilker TR, Schweigart U, Holscher AH, Siewert JR (1997) Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. *Transpl Int* 10: 229-33, http://www.maps.org/publications/1997_brauer_1.pdf
- Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxyamphetamine-induced neurotoxicity. *Pharmacol Biochem Behav* 45: 647-53, http://www.maps.org/publications/1993_brodkin_1.pdf
- Brody S, Krause C, Veit R, Rau H (1998) Cardiovascular autonomic dysregulation in users of MDMA ("Ecstasy"). *Psychopharmacology (Berl)* 136: 390-3, http://www.maps.org/publications/1998_brody_1.pdf
- Broening HW, Bacon L, Slikker W, Jr. (1994) Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 271: 285-93, http://www.maps.org/publications/1994_broening_1.pdf
- Broening HW, Bowyer JF, Slikker W, Jr. (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. *J Pharmacol Exp Ther* 275: 325-33, http://www.maps.org/publications/1995_broening_1.pdf
- Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV (2001) 3,4-Methylenedioxyamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development. *J Neurosci* 21: 3228-3235., http://www.maps.org/publications/2001_broening_1.pdf

- Bronson ME, Jiang W, Clark CR, DeRuiter J (1994) Effects of designer drugs on the chicken embryo and 1-day-old chicken. *Brain Res Bull* 34: 143-50, http://www.maps.org/publications/1994_bronson_2.pdf
- Bronson ME, Wages TD, Beddingfield T, Horner JM (1996) Morphine, MDMA, MDA, and nexus produce a conditioned place preference in newly hatched chickens. *Experimental & Clinical Psychopharmacology* 4: 354-362, http://www.maps.org/publications/1996_bronson_1.pdf
- Brorson JR, Schumacker PT, Zhang H (1999) Nitric oxide acutely inhibits neuronal energy production. *The Committees on Neurobiology and Cell Physiology. J Neurosci* 19: 147-58,
- Brown C, Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). *Jama* 258: 780-1, http://www.maps.org/publications/1987_brown_1.pdf
- Brownell AL, Jenkins BG, Isacson O (1999) Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. *Biomed Pharmacother* 53: 131-40,
- Bryden AA, Rothwell PJ, O'Reilly PH (1995) Urinary retention with misuse of "ecstasy". *Bmj* 310: 504, http://www.maps.org/publications/1995_bryden_1.pdf
- Buck A, Gucker PM, Schonbachler RD, Arigoni M, Kneifel S, Vollenweider FX, Ametamey SM, Burger C (2000) Evaluation of serotonergic transporters using PET and [¹¹C](+)-McN-5652: assessment of methods. *J Cereb Blood Flow Metab* 20: 253-62.,
- Buffum J, Moser C (1986) MDMA and human sexual function. *J Psychoactive Drugs* 18: 355-9, http://www.maps.org/publications/1986_buffum_1.pdf
- Burns N, Olverman HJ, Kelly PA, Williams BC (1996) Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. *Endocr Res* 22: 601-6, http://www.maps.org/publications/1996_burns_1.pdf
- Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. *Eur J Pharmacol* 398: 11-8, http://www.maps.org/publications/2000_burrows_1.pdf
- Burrows KB, Meshul CK (1999) High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. *Neuroscience* 90: 833-50,
- Buydens-Branchey L, Branchey M, Hudson J, Rothman M, Fergeson P, McKernin C (1999) Serotonergic function in cocaine addicts: prolactin responses to sequential D,L-fenfluramine challenges. *Biol Psychiatry* 45: 1300-6,
- Byard RW, Gilbert J, James R, Lokan RJ (1998) Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit? *Am J Forensic Med Pathol* 19: 261-5, http://www.maps.org/publications/1998_byard_1.pdf
- Byrne T, Baker LE, Poling A (2000) MDMA and learning: effects of acute and neurotoxic exposure in the rat. *Pharmacol Biochem Behav* 66: 501-8, http://www.maps.org/publications/2000_byrne_1.pdf
- Caccia S, Bergami A, Fracasso C, Garattini S, Campbell B (1995) Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. *Xenobiotica* 25: 1143-50,
- Caccia S, Sarati S, Anelli M, Garattini S (1992) Effect of escalating doses of d-fenfluramine on the content of indoles in brain. *Neuropharmacology* 31: 875-9,
- Cadet JL, Brannock C (1998) Free radicals and the pathobiology of brain dopamine systems. *Neurochem Int* 32: 117-31, http://www.maps.org/publications/1998_cadet_1.pdf
- Cadet JL, Ladenheim B, Baum I, Carlson E, Epstein C (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). *Brain Res* 655: 259-62, http://www.maps.org/publications/1994_cadet_1.pdf
- Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, Epstein C, Moran TH (1995) Superoxide radicals mediate the biochemical effects of methylenedioxyamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. *Synapse* 21: 169-76, http://www.maps.org/publications/1995_cadet_1.pdf
- Cadier MA, Clarke JA (1993) Ecstasy and Whizz at a rave resulting in a major burn plus complications. *Burns* 19: 239-40, http://www.maps.org/publications/1993_cadier_1.pdf
- Callahan BT, Cord BJ, Ricaurte GA (2001) Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxyamphetamine. *Synapse* 40: 113-121., http://www.maps.org/publications/2001_callahan_1.pdf

- Callaway CW, Geyer MA (1992) Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine_{1B} agonist. *J Pharmacol Exp Ther* 263: 318-26, http://www.maps.org/publications/1992_callaway_1.pdf
- Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. *Nature* 317: 246-8,
- Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. *J Clin Psychopharmacol* 20: 455-66, http://www.maps.org/publications/2000_cami_1.pdf
- Campbell DB (1995) The use of toxicokinetics for the safety assessment of drugs acting in the brain. *Mol Neurobiol* 11: 193-216, http://www.maps.org/publications/1995_campbell_1.pdf
- Campbell DB (1996) Extrapolation from animals to man: the integration of pharmacokinetics, and pharmacodynamics. *Ann N Y Acad Sci* 801: 116-135, http://www.maps.org/publications/1996_campbell_1.pdf
- Carvalho M, Carvalho F, Bastos ML (2001) Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. *Arch Toxicol* 74: 789-93., http://www.maps.org/publications/2001_carvalho_1.pdf
- Chait LD, Uhlenhuth EH, Johanson CE (1986) The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. *Psychopharmacology* 89: 301-6,
- Chan P, Chen JH, Lee MH, Deng JF (1994) Fatal and nonfatal methamphetamine intoxication in the intensive care unit. *J Toxicol Clin Toxicol* 32: 147-55,
- Chang L, Ernst T, Grob CS, Poland RE (1999) Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. *J Magn Reson Imaging* 10: 521-6, http://www.maps.org/publications/1999_chang_1.pdf
- Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. *Psychiatry Res* 98: 15-28, http://www.maps.org/publications/2000_chang_1.pdf
- Chang L, Mehringer CM, Ernst T, Melchor R, Myers H, Forney D, Satz P (1997) Neurochemical alterations in asymptomatic abstinent cocaine users: a proton magnetic resonance spectroscopy study. *Biol Psychiatry* 42: 1105-14,
- Che S, Johnson M, Hanson GR, Gibb JW (1995) Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. *Eur J Pharmacol* 293: 447-53, http://www.maps.org/publications/1995_che_1.pdf
- Chlopan BE, McCain ML, Carbonell JL, Hagen RL (1985) Empathy: Review of available measures. *Journal of Personality & Social Psychology* 48: 635-653,
- Cho AK, Hiramatsu M, Distefano EW, Chang AS, Jenden DJ (1990) Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. *Drug Metab Dispos* 18: 686-91, http://www.maps.org/publications/1990_cho_1.pdf
- Cho K, Ennaceur A, Cole JC, Suh CK (2000) Chronic jet lag produces cognitive deficits. *J Neurosci (Online)* 20: RC66,
- Choi DW (1992) Excitotoxic cell death. *J Neurobiol* 23: 1261-76,
- Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. *Biochem Pharmacol* 51: 789-96, http://www.maps.org/publications/1996_chu_1.pdf
- Clark AD, Butt N (1997) Ecstasy-induced very severe aplastic anaemia complicated by invasive pulmonary mucormycosis treated with allogeneic peripheral blood progenitor cell transplant. *Clin Lab Haematol* 19: 279-81, http://www.maps.org/publications/1997_clark_1.pdf
- Clarkson PM, Thompson HS (1997) Drugs and sport. Research findings and limitations. *Sports Med* 24: 366-84.,
- Coffey CE, Saxton JA, Ratcliff G, Bryan RN, Lucke JF (1999) Relation of education to brain size in normal aging: implications for the reserve hypothesis. *Neurology* 53: 189-96,
- Coffey SF, Dansky BS, Carrigan MH, Brady KT (2000) Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. *Drug Alcohol Depend* 59: 277-86,

- Cohen RS (1995) Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. *Prog Neuropsychopharmacol Biol Psychiatry* 19: 1137-45, http://www.maps.org/publications/1995_cohen_1.pdf
- Cohen RS (1996) Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy"). *Biol Psychiatry* 39: 819-20, http://www.maps.org/publications/1996_cohen_1.pdf
- Cohen RS, Cocores J (1997) Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy"). *Prog Neuropsychopharmacol Biol Psychiatry* 21: 727-34, http://www.maps.org/publications/1997_cohen_1.pdf
- Colado MI, Esteban B, O'Shea E, Granados R, Green AR (1999a) Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration. *Psychopharmacology (Berl)* 142: 421-5, http://www.maps.org/publications/1999_colado_1.pdf
- Colado MI, Granados R, O'Shea E, Esteban B, Green AR (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. *Br J Pharmacol* 124: 479-84, http://www.maps.org/publications/1998_colado_1.pdf
- Colado MI, Green AR (1994) A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5HT neurones using chlormethiazole, dizocilpine and other protective compounds. *Br J Pharmacol* 111: 131-6, http://www.maps.org/publications/1994_colado_1.pdf
- Colado MI, Green AR (1995) The spin trap reagent alpha-phenyl-N-tert-butyl nitron prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. *Eur J Pharmacol* 280: 343-6, http://www.maps.org/publications/1995_colado_1.pdf
- Colado MI, Murray TK, Green AR (1993) 5HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. *Br J Pharmacol* 108: 583-9, http://www.maps.org/publications/1993_colado_1.pdf
- Colado MI, O'Shea E, Esteban B, Granados R, Green AR (1999b) In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5HT nerve terminals by a free radical scavenging mechanism. *Neuropharmacology* 38: 307-14, http://www.maps.org/publications/1999_colado_2.pdf
- Colado MI, O'Shea E, Granados R, Esteban B, Martin AB, Green AR (1999c) Studies on the role of dopamine in the degeneration of 5HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. *Br J Pharmacol* 126: 911-24, http://www.maps.org/publications/1999_colado_3.pdf
- Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997a) A study of the neurotoxic effect of MDMA ('ecstasy') on 5HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. *Br J Pharmacol* 121: 827-33, http://www.maps.org/publications/1997_colado_1.pdf
- Colado MI, O'Shea E, Granados R, Murray TK, Green AR (1997b) In vivo evidence for free radical involvement in the degeneration of rat brain 5HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. *Br J Pharmacol* 121: 889-900, http://www.maps.org/publications/1997_colado_2.pdf
- Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. *Br J Pharmacol* 115: 1281-9, http://www.maps.org/publications/1995_colado_2.pdf
- Commins DL, Axt KJ, Vosmer G, Seiden LS (1987a) Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. *Brain Res* 419: 253-61,
- Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987b) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. *J Pharmacol Exp Ther* 241: 338-45, http://www.maps.org/publications/1987_commins_1.pdf
- Compan V, Segu L, Buhot MC, Daszuta A (1998) Differential effects of serotonin (5HT) lesions and synthesis blockade on neuropeptide-Y immunoreactivity and 5HT_{1A}, 5HT_{1B/1D} and 5HT_{2A/2C} receptor binding sites in the rat cerebral cortex. *Brain Res* 795: 264-76,

- Conner M, Sherlock K, Orbell S (1998) Psychosocial determinants of ecstasy use in young people in the UK. *British Journal of Health Psychology* 3: 295-317, http://www.maps.org/publications/1998_conner_1.pdf
- Connor TJ, Kelly JP, Leonard BE (2000a) An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats. *Immunopharmacology* 46: 223-35, http://www.maps.org/publications/2000_connor_1.pdf
- Connor TJ, Kelly JP, McGee M, Leonard BE (2000b) Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge. *Life Sci* 67: 1601-12, http://www.maps.org/publications/2000_connor_2.pdf
- Connor TJ, McNamara MG, Finn D, Currid A, O'Malley M, Redmond AM, Kelly JP, Leonard BE (1998) Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. *Immunopharmacology* 38: 253-60, http://www.maps.org/publications/1998_connor_1.pdf
- Convertino VA, Armstrong LE, Coyle EF, Mack GW, Sawka MN, Senay LC, Jr., Sherman WM (1996) American College of Sports Medicine position stand. Exercise and fluid replacement. *Med Sci Sports Exerc* 28: i-vii,
- Cox DE, Williams KR (1996) "ADAM" or "EVE"?--a toxicological conundrum [published erratum appears in *Forensic Sci Int* 1996 May 17;79(1):67]. *Forensic Sci Int* 77: 101-8, http://www.maps.org/publications/1996_cox_1.pdf
- Cregg MT, Tracey JA (1993) Ecstasy abuse in Ireland. *Ir Med J* 86: 118-20, http://www.maps.org/publications/1993_cregg_1.pdf
- Crifasi J, Long C (1996) Traffic fatality related to the use of methylenedioxymethamphetamine. *J Forensic Sci* 41: 1082-4, http://www.maps.org/publications/1996_crifasi_1.pdf
- Croft RJ, Mackay AJ, Mills AT, Gruzelier JG (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. *Psychopharmacology (Berl)* 153: 373-9., http://www.maps.org/publications/2001_croft_1.pdf
- Crompton M, Virji S, Doyle V, Johnson N, Ward JM (1999) The mitochondrial permeability transition pore. *Biochem Soc Symp* 66: 167-79,
- Cudennec A, Duverger D, Serrano A, Scatton B, MacKenzie ET (1988) Influence of ascending serotonergic pathways on glucose use in the conscious rat brain. II. Effects of electrical stimulation of the rostral raphe nuclei. *Brain Res* 444: 227-46,
- Curran HV (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. *Neuropsychobiology* 42: 34-41, http://www.maps.org/publications/2000_curran_1.pdf
- Curran HV, Travill RA (1997) Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. *Addiction* 92: 821-31, http://www.maps.org/publications/1997_curran_1.pdf
- Dafters RI (1994) Effect of ambient temperature on hyperthermia and hyperkinesia induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. *Psychopharmacology (Berl)* 114: 505-8, http://www.maps.org/publications/1994_dafters_1.pdf
- Dafters RI (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. *Physiol Behav* 58: 877-82, http://www.maps.org/publications/1995_dafters_1.pdf
- Dafters RI, Duffy F, O'Donnell PJ, Bouquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. *Psychopharmacology (Berl)* 145: 82-90, http://www.maps.org/publications/1999_dafters_1.pdf
- Dafters RI, Lynch E (1998) Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") but not by fenfluramine. *Psychopharmacology (Berl)* 138: 207-12, http://www.maps.org/publications/1998_dafters_1.pdf
- Dar KJ, McBrien ME (1996) MDMA induced hyperthermia: report of a fatality and review of current therapy. *Intensive Care Med* 22: 995-6, http://www.maps.org/publications/1996_dar_1.pdf
- Davies JP, Evans RO, Newington DP (1998) Ecstasy related trauma. *J Accid Emerg Med* 15: 436, http://www.maps.org/publications/1998_davies_1.pdf

- Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. *Psychiatry Res* 1: 249-54,
- Davis MH (1983) Measuring individual differences in empathy: Evidence for a multidimensional approach. *Journal of Personality & Social Psychology* 44: 113-126,
- Davis MH, Kraus LA (1997) *Personality and empathic accuracy Empathic accuracy*. The Guilford Press, New York, NY, USA, pp 144-168,
- Davis WM, Borne RF (1984) Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA). *Subst Alcohol Actions Misuse* 5: 105-10,
http://www.maps.org/publications/1984_davis_1.pdf
- Davis WM, Waters IW, Hatoum HT, Buelke JL, Braude MC (1977) Triphasic dose-lethality relationships for amphetamine and certain ring- substituted amphetamines in isolated or aggregated mice. *Res Commun Chem Pathol Pharmacol* 17: 575-82.,
- Davison D, Parrott AC (1997) Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects. *Human Psychopharmacology Clinical & Experimental* 12: 221-226,
http://www.maps.org/publications/1997_davison_1.pdf
- Daws EC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F (2000) Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. *Prog Neuropsychopharmacol Biol Psychiatry* 24: 955-77,
http://www.maps.org/publications/2000_daws_1.pdf
- de Boer D, Tan LP, Gorter P, van de Wal RM, Kettenes-van den Bosch JJ, de Bruijn EA, Maes RA (1997) Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. *J Mass Spectrom* 32: 1236-46,
http://www.maps.org/publications/1997_deboer_1.pdf
- de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000a) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. *Br J Clin Pharmacol* 49: 104-9,
http://www.maps.org/publications/2000_delatorre_1.pdf
- de la Torre R, Farre M, Roset PN, Hernandez Lopez C, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J (2000b) Pharmacology of MDMA in humans. *Ann N Y Acad Sci* 914: 225-37,
http://www.maps.org/publications/2000_delatorre_2.pdf
- De Souza EB, Battaglia G, Insel TR (1990) Neurotoxic effect of MDMA on brain serotonin neurons: evidence from neurochemical and radioligand binding studies. *Ann N Y Acad Sci* 600: 682-97; discussion 697-8, http://www.maps.org/publications/1990_desouza_1.pdf
- Delaforge M, Jaouen M, Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome p450: particular involvement of CYP 2D. *Environmental Toxicology and Pharmacology* 7: 7:153-158,
http://www.maps.org/publications/1999_delaforge_1.pdf
- Demirkiran M, Jankovic J, Dean JM (1996) Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. *Clin Neuropharmacol* 19: 157-64,
http://www.maps.org/publications/1996_demirkiran_1.pdf
- Denborough MA, Hopkinson KC (1997) Dantrolene and "ecstasy". *Med J Aust* 166: 165-6,
http://www.maps.org/publications/1997_denborough_1.pdf
- Depue RA, Spoont MR (1986) Conceptualizing a serotonin trait. A behavioral dimension of constraint. *Ann N Y Acad Sci* 487: 47-62,
- Derlet RW, Rice P, Horowitz BZ, Lord RV (1989) Amphetamine toxicity: experience with 127 cases. *J Emerg Med* 7: 157-61.,
- Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. *Mov Disord* 15: 459-66,
- Dierks T, Barta S, Demisch L, Schmeck K, Englert E, Kewitz A, Maurer K, Poustka F (1999) Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects [published erratum appears in *Psychopharmacology (Berl)* 2000 Apr;149(3):326]. *Psychopharmacology (Berl)* 146: 101-7,

- Dinges DF, Kribbs NB (1991) Performing while sleepy: Effects of experimentally-induced sleepiness. In: Monk TH (ed) Sleep, sleepiness and performance. John Wiley & Sons, New York, NY, pp 97-128,
- Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. *Pharmacopsychiatry* 31 Suppl 2: 80-4,
- Dornan WA, Katz JL, Ricaurte GA (1991) The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat. *Pharmacol Biochem Behav* 39: 813-6, http://www.maps.org/publications/1991_dornan_1.pdf
- Dowling GP, McDonough ETd, Bost RO (1987) 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. *Jama* 257: 1615-7, http://www.maps.org/publications/1987_dowling_1.pdf
- Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. *J Psychoactive Drugs* 18: 335-40, http://www.maps.org/publications/1986_downing_1.pdf
- Downing JJ (1985) Testimony of Joseph J. Downing, M.D. In the Matter of MDMA Scheduling. Docket No. 84-48. (United States Department of Justice, Drug Enforcement Administration)
- Drake WM, Broadhurst PA (1996) QT-interval prolongation with Ecstasy. *S Afr Med J* 86: 180-1, http://www.maps.org/publications/1996_drake_1.pdf
- Du L, Faludi G, Palkovits M, Demeter E, Bakish D, Lapierre YD, Sotonyi P, Hrdina PD (1999) Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. *Biol Psychiatry* 46: 196-201.,
- Duflo J, Mark A (2000) Aortic dissection after ingestion of "ecstasy" (MDMA). *Am J Forensic Med Pathol* 21: 261-3, http://www.maps.org/publications/2000_duflo_1.pdf
- Dupont RM, Jernigan TL, Butters N, Delis D, Hesselink JR, Heindel W, Gillin JC (1990) Subcortical abnormalities detected in bipolar affective disorder using magnetic resonance imaging. Clinical and neuropsychological significance. *Arch Gen Psychiatry* 47: 55-9.,
- Duxbury AJ (1993) Ecstasy--dental implications. *Br Dent J* 175: 38, http://www.maps.org/publications/1993_duxbury_1.pdf
- Dykens JA (1994) Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA²⁺ and Na⁺: implications for neurodegeneration. *J Neurochem* 63: 584-91,
- Dykhuisen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC (1995) Ecstasy induced hepatitis mimicking viral hepatitis. *Gut* 36: 939-41, http://www.maps.org/publications/1995_dykhuisen_1.pdf
- Eisenberg N, Miller PA (1987) The relation of empathy to prosocial and related behaviors. *Psychological Bulletin* 101: 91-119,
- Elayan I, Gibb JW, Hanson GR, Foltz RL, Lim HK, Johnson M (1992) Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine. *Eur J Pharmacol* 221: 281-8, http://www.maps.org/publications/1992_elayan_1.pdf
- Ellis AJ, Wendon JA, Portmann B, Williams R (1996) Acute liver damage and ecstasy ingestion. *Gut* 38: 454-8, http://www.maps.org/publications/1996_ellis_1.pdf
- Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. *Neurology* 54: 1344-9,
- Evenden JL (1999) Varieties of impulsivity. *Psychopharmacology* 146: 348-361,
- Eysenck SB, Pearson PR, Easting G, Allsopp JF (1985) Age norms for impulsiveness, venturesomeness and empathy in adults. *Personality & Individual Differences* 6: 613-619,
- Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans [published erratum appears in *Clin Chem* 1999 Sep;45(9):1585]. *Clin Chem* 45: 1058-69, http://www.maps.org/publications/1999_fallon_1.pdf
- Faraj BA, Olkowski ZL, Jackson RT (1994) Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. *Pharmacology* 48: 320-7,
- Farfel GM, Seiden LS (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. *J Pharmacol Exp Ther* 272: 860-7, http://www.maps.org/publications/1995_farfel_1.pdf
- Farfel GM, Vosmer GL, Seiden LS (1992) The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. *Brain Res* 595: 121-7, http://www.maps.org/publications/1992_farfel_1.pdf

- Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC (1998) Recent paramethoxyamphetamine deaths. *J Anal Toxicol* 22: 169-72, http://www.maps.org/publications/1998_felgate_1.pdf
- Fidler H, Dhillon A, Gertner D, Burroughs A (1996) Chronic ecstasy (3,4-methylenedioxymethamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. *J Hepatol* 25: 563-6, http://www.maps.org/publications/1996_fidler_1.pdf
- Finch E, Sell L, Arnold D (1996) Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Drug workers emphasise that water is not an antidote to drug. *Bmj* 313: 690, http://www.maps.org/publications/1996_finch_1.pdf
- Fineschi V, Centini F, Mazzeo E, Turillazzi E (1999) Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. *Forensic Sci Int* 104: 65-74, http://www.maps.org/publications/1999_fineschi_1.pdf
- Finnegan KT, Calder L, Clikeman J, Wei S, Karler R (1993) Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats. *Brain Res* 603: 134-8, http://www.maps.org/publications/1993_finnegan_1.pdf
- Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW (1988) Orally administered MDMA causes a long-term depletion of serotonin in rat brain. *Brain Res* 447: 141-4, http://www.maps.org/publications/1988_finnegan_1.pdf
- Finnegan KT, Skratt JJ, Irwin I, Langston JW (1990) The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. *Neurosci Lett* 105: 300-6, http://www.maps.org/publications/1990_finnegan_1.pdf
- Finnegan KT, Taraska T (1996) Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo. *J Neurochem* 66: 1949-58, http://www.maps.org/publications/1996_finnegan_1.pdf
- Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995) Reorganization of ascending 5HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). *J Neurosci* 15: 5476-85, http://www.maps.org/publications/1995_fischer_1.pdf
- Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A (2000) MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. *Eur J Neurosci* 12: 1385-90, http://www.maps.org/publications/2000_fischer_1.pdf
- Fischette CT, Nock B, Renner K (1987) Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography. *Brain Res* 421: 263-79,
- Fitzgerald JL, Reid JJ (1994) Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. *J Pharm Pharmacol* 46: 826-32, http://www.maps.org/publications/1994_fitzgerald_1.pdf
- Fitzgerald RL, Blanke RV, Poklis A (1990) Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. *Chirality* 2: 241-8, http://www.maps.org/publications/1990_fitzgerald_2.pdf
- Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW, Hanson GR (1999) Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. *Eur J Pharmacol* 382: 45-9, http://www.maps.org/publications/1999_fleckenstein_1.pdf
- Forsyth AJ (1996) Places and patterns of drug use in the Scottish dance scene. *Addiction* 91: 511-21, http://www.maps.org/publications/1996_forsyth_1.pdf
- Forsyth AJ, Barnard M, McKeganey NP (1997) Musical preference as an indicator of adolescent drug use. *Addiction* 92: 1317-25, http://www.maps.org/publications/1997_forsyth_1.pdf
- Fossati P, Amar G, Raoux N, Ergis AM, Allilaire JF (1999) Executive functioning and verbal memory in young patients with unipolar depression and schizophrenia. *Psychiatry Res* 89: 171-87.,
- Fraser CL, Arief AI (1997) Epidemiology, pathophysiology, and management of hyponatremic encephalopathy [see comments]. *Am J Med* 102: 67-77,
- Frederick DL, Ali SF, Gillam MP, Gossett J, Slikker W, Paule MG (1998) Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. *Ann N Y Acad Sci* 844: 183-90, http://www.maps.org/publications/1998_frederick_1.pdf

- Frederick DL, Ali SF, Slikker W, Jr., Gillam MP, Allen RR, Paule MG (1995) Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. *Neurotoxicol Teratol* 17: 531-43, http://www.maps.org/publications/1995_frederick_1.pdf
- Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. *Eur J Pharmacol* 334: 273-9,
- Frith CH, Chang LW, Lattin DL, Walls RC, Hamm J, Doblin R (1987) Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. *Fundam Appl Toxicol* 9: 110-9, http://www.maps.org/publications/1987_frith_1.pdf
- Fritschy JM, Lyons WE, Molliver ME, Grzanna R (1988) Neurotoxic effects of p-chloroamphetamine on the serotonergic innervation of the trigeminal motor nucleus: a retrograde transport study. *Brain Res* 473: 261-70,
- Frost M, Kohler H, Blaschke G (1996) Analysis of "Ecstasy" by capillary electrophoresis. *Int J Legal Med* 109: 53-7, http://www.maps.org/publications/1996_frost_1.pdf
- Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000a) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. *Neuropsychopharmacology* 23: 388-95, http://www.maps.org/publications/2000_gamma_1.pdf
- Gamma A, Buck A, Berthold T, Vollenweider FX (2001) No difference in brain activation during cognitive performance between Ecstasy (MDMA) users and controls: a [H215O]-PET study. *Journal of Clinical Psychopharmacology* 21: 66-71, http://www.maps.org/publications/2001_gamma_1.pdf
- Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000b) Mood state and brain electric activity in ecstasy users. *Neuroreport* 11: 157-62, http://www.maps.org/publications/2000_gamma_2.pdf
- Garrett ER, Seyda K, Marroum P (1991) High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding. *Acta Pharm Nord* 3: 9-14, http://www.maps.org/publications/1991_garrett_1.pdf
- Gartside SE, McQuade R, Sharp T (1996) Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. *J Pharmacol Exp Ther* 279: 277-83, http://www.maps.org/publications/1996_gartside_1.pdf
- Gasser P (1994) Psycholytic Therapy with MDMA and LSD in Switzerland. *MAPS Newsletter* 5: 3-7,
- Gaston TR, Rasmussen GT (1972) Identification of 3,4-methylenedioxymethamphetamine. *BNDD Laboratory Notes*: 60-63, http://www.maps.org/publications/1972_gaston_1.pdf
- Gaylor DW, Slikker W, Jr. (1990) Risk assessment for neurotoxic effects. *Neurotoxicology* 11: 211-8, http://www.maps.org/publications/1990_gaylor_1.pdf
- Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F (2000) Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. *Biol Psychiatry* 47: 127-36, http://www.maps.org/publications/2000_gerra_1.pdf
- Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R (1998) Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. *Int Clin Psychopharmacol* 13: 1-9, http://www.maps.org/publications/1998_gerra_1.pdf
- Geyer MA, Puerto A, Menkes DB, Segal DS, Mandell AJ (1976) Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. *Brain Res* 106: 257-69.,
- Gibb JW, Johnson M, Elayan I, Lim HK, Matsuda L, Hanson GR (1997) Neurotoxicity of amphetamines and their metabolites. *NIDA Res Monogr* 173: 128-45, http://www.maps.org/publications/1997_gibb_1.pdf
- Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF (1999) MDMA study. *Neuropsychopharmacology* 21: 597, http://www.maps.org/publications/1999_gijsman_1.pdf
- Gillen RW, Kranzler HR, Bauer LO, Bursleson JA, Samarel D, Morrison DJ (1998) Neuropsychologic findings in cocaine-dependent outpatients. *Prog Neuropsychopharmacol Biol Psychiatry* 22: 1061-76.,

- Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoid haemorrhage associated with MDMA abuse. *J Neurol Neurosurg Psychiatry* 56: 1036-7,
http://www.maps.org/publications/1993_gledhill_1.pdf
- Globus MY, Busto R, Lin B, Schnippering H, Ginsberg MD (1995) Detection of free radical activity during transient global ischemia and recirculation: effects of intras ischemic brain temperature modulation. *J Neurochem* 65: 1250-6,
- Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, Leakey JE, Kolta M, Slikker W, Jr. (1989) Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. *Neurotoxicology* 10: 455-66,
http://www.maps.org/publications/1989_gollamudi_1.pdf
- Gomez-Balaguer M, Pena H, Morillas C, Hernandez A (2000) Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (ecstasy). *J Pediatr Endocrinol Metab* 13: 437-8,
http://www.maps.org/publications/2000_gomezbalaguer_1.pdf
- Gorard DA, Davies SE, Clark ML (1992) Misuse of ecstasy. *Bmj* 305: 309,
http://www.maps.org/publications/1992_gorard_1.pdf
- Gordon CJ, Fogelson L (1994) Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: implications for pharmacological studies. *Physiol Behav* 56: 73-9,
http://www.maps.org/publications/1994_gordon_1.pdf
- Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. *Pharmacol Biochem Behav* 38: 339-44,
http://www.maps.org/publications/1991_gordon_1.pdf
- Gore SM (1999) Fatal uncertainty: death-rate from use of ecstasy or heroin. *Lancet* 354: 1265-6,
http://www.maps.org/publications/1999_gore_1.pdf
- Gough B, Ali SF, Slikker W, Jr., Holson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. *Pharmacol Biochem Behav* 39: 619-23,
http://www.maps.org/publications/1991_gough_1.pdf
- Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). *J Neurol Neurosurg Psychiatry* 68: 719-25,
http://www.maps.org/publications/2000_gouzoulismayfrank_1.pdf
- Gouzoulis-Mayfrank E, Schneider F, Friedrich J, Spitzer M, Thelen B, Sass H (1998) Methodological issues of human experimental research with hallucinogens. *Pharmacopsychiatry* 31 Suppl 2: 114-8,
- Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H (1999a) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [¹⁸F]FDG. *Neuropsychopharmacology* 20: 565-81,
- Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999b) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo- controlled study. *Psychopharmacology (Berl)* 142: 41-50,
- Graham DG, Tiffany SM, Bell WR, Jr., Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. *Mol Pharmacol* 14: 644-53,
- Granoff MI, Ashby CR, Jr. (1998) The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5HT_{2A,C} receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). *Neuropsychobiology* 37: 36-40,
http://www.maps.org/publications/1998_granoff_1.pdf
- Graves AB, Mortimer JA, Larson EB, Wenzlow A, Bowen JD, McCormick WC (1996) Head circumference as a measure of cognitive reserve. Association with severity of impairment in Alzheimer's disease. *Br J Psychiatry* 169: 86-92,
- Greer G (1985) Testimony of George Greer, M.D. in DEA Hearing on Scheduling MDMA Under the Controlled Substances Act. In the Matter of MDMA Scheduling. Docket No. 84-48. (United States Department of Justice, Drug Enforcement Administration.)

- Greer G, Strassman RJ (1985) Information on "Ecstasy". *Am J Psychiatry* 142: 1391, http://www.maps.org/publications/1985_greer_1.pdf
- Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. *J Psychoactive Drugs* 18: 319-27, http://www.maps.org/publications/1986_greer_1.pdf
- Greer G, Tolbert R (1990) The therapeutic use of MDMA. In: Peroutka SJ (ed) *Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA*. Kluwer Academic Publishers, Boston, pp 21-36,
- Greer GR, Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. *J Psychoactive Drugs* 30: 371-9. http://www.maps.org/publications/1998_greer_1.pdf
- Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? *Am J Psychother* 40: 393-404, http://www.maps.org/publications/1986_grinspoon_1.pdf
- Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. *Behav Brain Res* 73: 103-7, http://www.maps.org/publications/1996_grob_1.pdf
- Grob CS, Poland RE, others (In preparation) Psychological, physiological and neuroendocrine effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in healthy humans.:
- Gudelsky GA (1996) Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. *J Neural Transm* 103: 1397-404, http://www.maps.org/publications/1996_gudelsky_2.pdf
- Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. *J Neurochem* 66: 243-9, http://www.maps.org/publications/1996_gudelsky_1.pdf
- Gudelsky GA, Yamamoto BK, Nash JF (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5HT₂ receptor agonists. *Eur J Pharmacol* 264: 325-30, http://www.maps.org/publications/1994_gudelsky_1.pdf
- Haertzen CA (1966) Development of Scales Based on Patterns of Drug Effects, Using the Addiction Research Center Inventory (Arci). *Psychological Reports* 18: 163-194,
- Hall AP (1997a) Dantrolene and "ecstasy". *Med J Aust* 167: 506-7, http://www.maps.org/publications/1997_hall_4.pdf
- Hall AP (1997b) Hyponatraemia, water intoxication and 'ecstasy'. *Intensive Care Med* 23: 1289, http://www.maps.org/publications/1997_hall_1.pdf
- Hammersley R, Ditton J, Smith I, Short E (1999) Patterns of ecstasy use by drug users. *British Journal of Criminology* 39: 625-647, http://www.maps.org/publications/1999_hammersley_1.pdf
- Haring JH, Meyerson L, Hoffman TL (1992) Effects of para-chloroamphetamine upon the serotonergic innervation of the rat hippocampus. *Brain Res* 577: 253-60,
- Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. *Brain Res* 871: 259-70,
- Hashimoto K, Goromaru T (1990) Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine. *Fundam Clin Pharmacol* 4: 635-41, http://www.maps.org/publications/1990_hashimoto_2.pdf
- Hashimoto K, Maeda H, Goromaru T (1992a) Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine. *Eur J Pharmacol* 228: 171-4, http://www.maps.org/publications/1992_hashimoto_2.pdf
- Hashimoto K, Maeda H, Goromaru T (1992b) Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain. *Brain Res* 590: 341-4, http://www.maps.org/publications/1992_hashimoto_1.pdf
- Hastings A (1994) Some observations on MDMA experiences induced through posthypnotic suggestion. *J Psychoactive Drugs* 26: 77-83, http://www.maps.org/publications/1994_hastings_1.pdf
- Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. *J Neurosci* 19: 5096-107, http://www.maps.org/publications/1999_hatzidimitriou_1.pdf
- Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. *Neurosci Biobehav Rev* 23: 539-53, http://www.maps.org/publications/1999_hegadoren_1.pdf

- Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. *J Neurochem* 66: 2621-4.,
- Heinz A, Jones DW (2000) Serotonin transporters in ecstasy users. *Br J Psychiatry* 176: 193-5, http://www.maps.org/publications/2000_heinz_1.pdf
- Hekmatpanah CR, McKenna DJ, Peroutka SJ (1989) Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. *Neurosci Lett* 104: 178-82, http://www.maps.org/publications/1989_hekmatpanah_1.pdf
- Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. *J Anal Toxicol* 20: 432-40, http://www.maps.org/publications/1996_helmlin_1.pdf
- Helmlin HJ, Brenneisen R (1992) Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection. *J Chromatogr* 593: 87-94, http://www.maps.org/publications/1992_helmlin_1.pdf
- Henry JA (2000) Metabolic consequences of drug misuse. *Br J Anaesth* 85: 136-42, http://www.maps.org/publications/2000_henry_1.pdf
- Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M (1998) Low-dose MDMA ("ecstasy") induces vasopressin secretion. *Lancet* 351: 1784, http://www.maps.org/publications/1998_henry_1.pdf
- Henry JA, Hill IR (1998) Fatal interaction between ritonavir and MDMA. *Lancet* 352: 1751-2, http://www.maps.org/publications/1998_henry_2.pdf
- Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). *Lancet* 340: 384-7, http://www.maps.org/publications/1992_henry_1.pdf
- Hensley D, Cody JT (1999) Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS. *J Anal Toxicol* 23: 518-23, http://www.maps.org/publications/1999_hensley_1.pdf
- Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. *Biol Psychiatry* 32: 976-91,
- Herning RI, Guo X, Better WE, Weinhold LL, Lange WR, Cadet JL, Gorelick DA (1997) Neurophysiological signs of cocaine dependence: increased electroencephalogram beta during withdrawal. *Biol Psychiatry* 41: 1087-94,
- Herning RI, King DE, Better WE, Cadet JL (1999) Neurovascular deficits in cocaine abusers. *Neuropsychopharmacology* 21: 110-8,
- Hervias I, Lasheras B, Aguirre N (2000) 2-Deoxy-D-glucose prevents and nicotinamide potentiates 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity. *J Neurochem* 75: 982-90, http://www.maps.org/publications/2000_hervias_1.pdf
- Hewitt KE, Green AR (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. *Neuropharmacology* 33: 1589-95, http://www.maps.org/publications/1994_hewitt_1.pdf
- Heym J, Gladfelter WE (1982) Locomotor activity and ingestive behavior after damage to ascending serotonergic systems. *Physiol Behav* 29: 459-67,
- Hiramatsu M, Cho AK (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. *Neuropharmacology* 29: 269-75, http://www.maps.org/publications/1990_hiramatsu_1.pdf
- Hiramatsu M, Kumagai Y, Unger SE, Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. *J Pharmacol Exp Ther* 254: 521-7, http://www.maps.org/publications/1990_hiramatsu_2.pdf
- Hiratsuka A, Chu TY, Distefano EW, Lin LY, Schmitz DA, Cho AK (1995) Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat. *Drug Metab Dispos* 23: 201-6, http://www.maps.org/publications/1995_hiratsuka_1.pdf
- Holden R, Jackson MA (1996) Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). *Lancet* 347: 1052, http://www.maps.org/publications/1996_holden_1.pdf

- Holman BL, Mendelson J, Garada B, Teoh SK, Hallgring E, Johnson KA, Mello NK (1993) Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. *J Nucl Med* 34: 723-7,
- Holmes SB, Banerjee AK, Alexander WD (1999) Hyponatraemia and seizures after ecstasy use. *Postgrad Med J* 75: 32-3, http://www.maps.org/publications/1999_holmes_1.pdf
- Hoofst P, van de Voorde HP (1994) Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing. *Int J Legal Med* 106: 328-9, http://www.maps.org/publications/1994_hoofst_1.pdf
- Horan B, Gardner EL, Ashby CR, Jr. (2000) Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3, 4-methylenedioxymethamphetamine (MDMA). *Synapse* 35: 160-2, http://www.maps.org/publications/2000_horan_1.pdf
- Horton AA, Fairhurst S (1987) Lipid peroxidation and mechanisms of toxicity. *Crit Rev Toxicol* 18: 27-79,
- House RV, Thomas PT, Bhargava HN (1995) Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). *Toxicology* 96: 59-69, http://www.maps.org/publications/1995_house_1.pdf
- Hubner CB, Bird M, Rassnick S, Kornetsky C (1988) The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. *Psychopharmacology (Berl)* 95: 49-51, http://www.maps.org/publications/1988_hubner_1.pdf
- Huether G, Zhou D, Ruther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. *J Neural Transm* 104: 771-94, http://www.maps.org/publications/1997_huether_1.pdf
- Hughes JC, McCabe M, Evans RJ (1993) Intracranial haemorrhage associated with ingestion of 'ecstasy'. *Arch Emerg Med* 10: 372-4, http://www.maps.org/publications/1993_hughes_1.pdf
- Ickes W, Stinson L, Bissonette V, Garcia S (1990) Naturalistic social cognition: Empathic accuracy in mixed-sex dyads. *Journal of Personality & Social Psychology* 59: 730-742,
- Ingrasci R (1985) Testimony for MDMA Hearing Submitted by Richard Ingrasci, M.D., M.P.H. In the Matter of MDMA Scheduling. Docket No. 84-48. (United States Department of Justice, Drug Enforcement Administration.)
- Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB (1989) 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. *J Pharmacol Exp Ther* 249: 713-20, http://www.maps.org/publications/1989_insel_1.pdf
- Jacks AS, Hykin PG (1998) Retinal haemorrhage caused by "ecstasy". *Br J Ophthalmol* 82: 842-3, http://www.maps.org/publications/1998_jacks_1.pdf
- Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB (2000) Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. *Am J Psychiatry* 157: 1134-40,
- Jagust WJ, Eberling JL, Biegon A, Taylor SE, VanBrocklin HF, Jordan S, Hanrahan SM, Roberts JA, Brennan KM, Mathis CA (1996) Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. *J Nucl Med* 37: 1207-14, http://www.maps.org/publications/1996_jagust_1.pdf
- Jayanthi S, Ladenheim B, Andrews AM, Cadet JL (1999) Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). *Neuroscience* 91: 1379-87, http://www.maps.org/publications/1999_jayanthi_1.pdf
- Jensen KF, Olin J, Haykal-Coates N, O'Callaghan J, Miller DB, de Olmos JS (1993) Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine. *NIDA Res Monogr* 136: 133-49; discussion 150-4, http://www.maps.org/publications/1993_jensen_1.pdf
- Jiang XR, Wrona MZ, Dryhurst G (1999) Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: possible implications in neurodegenerative brain disorders. *Chem Res Toxicol* 12: 429-36,
- Johanson CE, Uhlenhuth EH (1980) Drug preference and mood in humans: d-amphetamine. *Psychopharmacology* 71: 275-9,
- Johnson M, Bush LG, Hanson GR, Gibb JW (1993) Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the

- increase in striatal neurotensin and dynorphin A concentrations. *Biochem Pharmacol* 46: 770-2, http://www.maps.org/publications/1993_johnson_1.pdf
- Johnson M, Elayan I, Hanson GR, Foltz RL, Gibb JW, Lim HK (1992a) Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. *J Pharmacol Exp Ther* 261: 447-53, http://www.maps.org/publications/1992_johnson_1.pdf
- Johnson M, Mitros K, Stone DM, Zobrist R, Hanson GR, Gibb JW (1992b) Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 261: 586-91, http://www.maps.org/publications/1992_johnson_2.pdf
- Johnson M, Stone DM, Bush LG, Hanson GR, Gibb JW (1989) Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. *Eur J Pharmacol* 161: 181-8, http://www.maps.org/publications/1989_johnson_2.pdf
- Johnson MP, Conarty PF, Nichols DE (1991) [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. *Eur J Pharmacol* 200: 9-16, http://www.maps.org/publications/1991_johnson_1.pdf
- Johnston LD, O'Malley PM, Bachman JG (2000a) Monitoring the Future: National Survey Results on Drug Abuse, 1975-1999, Vol. 1 Secondary School Students. National Institute on Drug Abuse, National Institute on Drug Abuse,
- Johnston LD, O'Malley PM, Bachman JG (2000b) Monitoring the Future: National Survey Results on Drug Abuse, 1975-1999, Vol. 2 College Students and Adults Ages 19-40. National Institute on Drug Abuse, National Institute on Drug Abuse,
- Jones AL, Simpson KJ (1999) Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. *Aliment Pharmacol Ther* 13: 129-33, http://www.maps.org/publications/1999_jones_1.pdf
- Kaku DA, Lowenstein DH (1990) Emergence of recreational drug abuse as a major risk factor for stroke in young adults. *Ann Intern Med* 113: 821-7.,
- Kalia M, O'Callaghan JP, Miller DB, Kramer M (2000) Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. *Brain Res* 858: 92-105, http://www.maps.org/publications/2000_kalia_1.pdf
- Kalivas PW, Duffy P, White SR (1998) MDMA elicits behavioral and neurochemical sensitization in rats. *Neuropsychopharmacology* 18: 469-79, http://www.maps.org/publications/1998_kalivas_1.pdf
- Kaskey GB (1992) Possible interaction between an MAOI and "ecstasy". *Am J Psychiatry* 149: 411-2, http://www.maps.org/publications/1992_kaskey_1.pdf
- Katz MM, Waskow IE, Olsson J (1968) Characterizing the psychological state produced by LSD. *J Abnorm Psychol* 73: 1-14,
- Kauvar SS, Henschel EJ, Ravin A (1943) Toxic eruption due to amphetamine sulfate and its analogue dextroamphetamine sulphate. *Journal of the American Medical Association* 122: 1073-1074,
- Kelland MD, Freeman AS, Chiodo LA (1989) (+/-)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. *Eur J Pharmacol* 169: 11-21, http://www.maps.org/publications/1989_kelland_1.pdf
- Kelly PA, Ritchie IM, Sangra M, Cursham MJ, Dickson EM, Kelly B, Neilson FP, Reidy MJ, Stevens MC (1994) Hyperaemia in rat neocortex produced by acute exposure to methylenedioxymethamphetamine. *Brain Res* 665: 315-8, http://www.maps.org/publications/1994_kelly_1.pdf
- Kessel B (1994) Hyponatraemia after ingestion of ecstasy. *Bmj* 308: 414, http://www.maps.org/publications/1994_kessel_1.pdf
- Khakoo SI, Coles CJ, Armstrong JS, Barry RE (1995) Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage. *J Clin Gastroenterol* 20: 244-7, http://www.maps.org/publications/1995_khakoo_1.pdf
- Kirby LG, Kreiss DS, Singh A, Lucki I (1995) Effect of destruction of serotonin neurons on basal and fenfluramine- induced serotonin release in striatum. *Synapse* 20: 99-105,
- Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. *Neurology* 55: 294-6, http://www.maps.org/publications/2000_kish_1.pdf

- Kleven MS, Woolverton WL, Seiden LS (1989) Evidence that both intragastric and subcutaneous administration of methylenedioxyamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. *Brain Res* 488: 121-5, http://www.maps.org/publications/1989_kleven_1.pdf
- Klitzman RL, Pope HG, Jr., Hudson JI (2000) MDMA ("Ecstasy") abuse and high-risk sexual behaviors among 169 gay and bisexual men. *Am J Psychiatry* 157: 1162-4, http://www.maps.org/publications/2000_klitzman_1.pdf
- Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW (1998) Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. *Drug Alcohol Depend* 50: 187-95,
- Kovacs GL, Bohus B, Versteeg DH (1979) Facilitation of memory consolidation by vasopressin: mediation by terminals of the dorsal noradrenergic bundle? *Brain Res* 172: 73-85,
- Kramer HK, Poblete JC, Azmitia EC (1998) Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxyamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT). *Neuropsychopharmacology* 19: 265-77, http://www.maps.org/publications/1998_kramer_1.pdf
- Kreth K, Kovar K, Schwab M, Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. *Biochem Pharmacol* 59: 1563-71, http://www.maps.org/publications/2000_kreth_1.pdf
- Kretsch MJ, Green MW, Fong AK, Elliman NA, Johnson HL (1997) Cognitive effects of a long-term weight reducing diet. *Int J Obes Relat Metab Disord* 21: 14-21,
- Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-methylenedioxyamphetamine (MDMA) use: effects on mood and neuropsychological function? *Am J Drug Alcohol Abuse* 18: 331-41, http://www.maps.org/publications/1992_krystal_1.pdf
- Kuikka JT, Ahonen AK (1999) Toxic effect of MDMA on brain serotonin neurons. *Lancet* 353: 1269; discussion 1270-1, http://www.maps.org/publications/1999_kuikka_1.pdf
- Kumagai Y, Wickham KA, Schmitz DA, Cho AK (1991) Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethylenation reaction. *Biochem Pharmacol* 42: 1061-7, http://www.maps.org/publications/1991_kumagai_1.pdf
- Kurova T, Shoubnikova, M., Malceva, A., & Mardh, P. A. (1998) Prostitution in Riga, Latvia - A socio-medical matter of concern. *Acta Obstetrica et Gynecologica Scandinavica*, 77: 83-86,
- Lamb RJ, Griffiths RR (1987) Self-injection of d,l-3,4-methylenedioxyamphetamine (MDMA) in the baboon. *Psychopharmacology (Berl)* 91: 268-72, http://www.maps.org/publications/1987_lamb_1.pdf
- Langs RJ, Barr HL (1968) Lysergic acid diethylamide (LSD-25) and schizophrenic reactions. A comparative study. *J Nerv Ment Dis* 147: 163-72,
- Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219: 979-80,
- Lanz M, Brenneisen R, Thormann W (1997) Enantioselective determination of 3,4-methylenedioxyamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. *Electrophoresis* 18: 1035-43,
- Lavelle A, Honner V, Docherty JR (1999) Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. *Br J Pharmacol* 128: 975-80, http://www.maps.org/publications/1999_lavelle_1.pdf
- Laviola G, Adriani W, Terranova ML, Gerra G (1999) Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. *Neurosci Biobehav Rev* 23: 993-1010, http://www.maps.org/publications/1999_laviola_1.pdf
- LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. *J Neurosci* 19: 1484-91,
- Layton JM, Wykle MH (1990) A validity study of four empathy instruments. *Research in Nursing & Health* 13: 319-325,
- Le Poul E, Boni C, Hanoun N, Laporte AM, Laaris N, Chauveau J, Hamon M, Lanfumey L (2000) Differential adaptation of brain 5HT_{1A} and 5HT_{1B} receptors and 5HT transporter in rats treated chronically with fluoxetine. *Neuropharmacology* 39: 110-22,

- Lehmann ED, Thom CH, Croft DN (1995) Delayed severe rhabdomyolysis after taking 'ecstasy'. *Postgrad Med J* 71: 186-7, http://www.maps.org/publications/1995_lehmann_1.pdf
- Lenton S, Boys A, Norcross K (1997) Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. *Addiction* 92: 1327-37, http://www.maps.org/publications/1997_lenton_1.pdf
- LeSage M, Clark R, Poling A (1993) MDMA and memory: the acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure. *Psychopharmacology (Berl)* 110: 327-32, http://www.maps.org/publications/1993_lesage_1.pdf
- Lesch KP, Heils A, Riederer P (1996) The role of neurotransmitters in excitotoxicity, neuronal cell death, and other neurodegenerative processes. *J Mol Med* 74: 365-78, http://www.maps.org/publications/1996_lesch_1.pdf
- Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine. A Double- Blind, Placebo-Controlled Trial. *Ann Intern Med* 133: 969-973, http://www.maps.org/publications/2001_lester_1.pdf
- Levine AJ, Drew S, Rees GM (1993) 'Ecstasy' induced pneumomediastinum. *J R Soc Med* 86: 232-3, http://www.maps.org/publications/1993_levine_1.pdf
- Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. *J Pharmacol Exp Ther* 276: 855-65, http://www.maps.org/publications/1996_lew_1.pdf
- Lewis LA, Ross MW (1995) The gay dance party culture in Sydney: a qualitative analysis. *J Homosex* 29: 41-70, http://www.maps.org/publications/1995_lewis_1.pdf
- Lezak MD (1995) *Neuropsychological Assessment*, 3rd edn. Oxford University Press, Oxford University Press,
- Li AA, Marek GJ, Vosmer G, Seiden LS (1989) Long-term central 5HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats. *Pharmacol Biochem Behav* 33: 641-8, http://www.maps.org/publications/1989_li_1.pdf
- Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. *Neuropsychopharmacology* 22: 513-21, http://www.maps.org/publications/2000_liechti_1.pdf
- Liechti ME, Gamma A, Vollenweider FX (2001a) Gender differences in the subjective effects of MDMA. *Psychopharmacology on-line publication*. http://www.maps.org/publications/2001_liechti_1.pdf
- Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001b) Effects of MDMA (Ecstasy) on pre-pulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. *Neuropsychopharmacology* 24: 240-252, http://www.maps.org/publications/2001_liechti_2.pdf
- Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5HT(2) antagonist ketanserin in healthy humans. *Neuropsychopharmacology* 23: 396-404, http://www.maps.org/publications/2000_liechti_2.pdf
- Liechti ME, Vollenweider FX (2000a) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. *Eur Neuropsychopharmacol* 10: 289-95, http://www.maps.org/publications/2000_liechti_1.pdf
- Liechti ME, Vollenweider FX (2000b) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. *J Psychopharmacol* 14: 269-74, http://www.maps.org/publications/2000_liechti_4.pdf
- Lieberman MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. *J Nerv Ment Dis* 180: 345-52; discussion 353-4, http://www.maps.org/publications/1992_liester_1.pdf
- Lim HK, Foltz RL (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. *Chem Res Toxicol* 1: 370-8, http://www.maps.org/publications/1988_lim_1.pdf

- Lim HK, Foltz RL (1989) Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine. *Chem Res Toxicol* 2: 142-3, http://www.maps.org/publications/1989_lim_1.pdf
- Lim HK, Foltz RL (1991) In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques. *Biol Mass Spectrom* 20: 677-86, http://www.maps.org/publications/1991_lim_1.pdf
- Lin HQ, Atrens DM, Christie MJ, Jackson DM, McGregor IS (1993) Comparison of conditioned taste aversions produced by MDMA and d-amphetamine. *Pharmacol Biochem Behav* 46: 153-6, http://www.maps.org/publications/1993_lin_1.pdf
- Lin HQ, Jackson DM, Atrens DM, Christie MJ, McGregor IS (1997a) Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. *Brain Res* 744: 351-7, http://www.maps.org/publications/1997_lin_1.pdf
- Lin JH (1998) Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. *Drug Metab Dispos* 26: 1202-12,
- Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK (1997b) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. *Drug Metab Dispos* 25: 1059-64, http://www.maps.org/publications/1997_lin_2.pdf
- Lin LY, Kumagai Y, Cho AK (1992) Enzymatic and chemical demethylation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. *Chem Res Toxicol* 5: 401-6, http://www.maps.org/publications/1992_lin_1.pdf
- Lind J, Oyefeso A, Pollard M, Baldacchino A, Ghodse H (1999) Death rate from use of ecstasy or heroin. *Lancet* 354: 2167, http://www.maps.org/publications/1999_lind_1.pdf
- Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR, DelProposto ZS, Hill E, Cassin BJ, Watson SJ, Cook EH (1998) Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. *Am J Psychiatry* 155: 207-13,
- Logan AS, Stickle B, O'Keefe N, Hewitson H (1993) Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. *Anaesthesia* 48: 1017-8, http://www.maps.org/publications/1993_logan_1.pdf
- Logan BJ, Laverty R, Sanderson WD, Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. *Eur J Pharmacol* 152: 227-34, http://www.maps.org/publications/1988_logan_1.pdf
- Lorens SA, Hata N, Cabrera T, Hamilton ME (1989) Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine. *NIDA Res Monogr* 95: 347, http://www.maps.org/publications/1989_lorens_1.pdf
- Lu D, Das DK (1993) Induction of differential heat shock gene expression in heart, lung, liver, brain and kidney by a sympathomimetic drugs amphetamine. *Biochem Biophys Res Comm* 192: 808-812,
- MacConnachie AM (1997) Ecstasy poisoning. *Intensive Crit Care Nurs* 13: 365-6, http://www.maps.org/publications/1997_macconnachie_1.pdf
- Magee C, Staunton H, Tormey W, Walshe JJ (1998) Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. *Ir Med J* 91: 178, http://www.maps.org/publications/1998_magee_1.pdf
- Malberg JE, Sabol KE, Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. *J Pharmacol Exp Ther* 278: 258-67, http://www.maps.org/publications/1996_malberg_1.pdf
- Malberg JE, Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. *J Neurosci* 18: 5086-94, http://www.maps.org/publications/1998_malberg_1.pdf
- Mallick A, Bodenham AR (1997) MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. *J Accid Emerg Med* 14: 336-8, http://www.maps.org/publications/1997_mallick_1.pdf
- Manchanda S, Connolly MJ (1993) Cerebral infarction in association with Ecstasy abuse. *Postgrad Med J* 69: 874-5, http://www.maps.org/publications/1993_manchanda_1.pdf

- Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH (1996) The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. *Drug Metab Dispos* 24: 555-9,
- Marchant NC, Breen MA, Wallace D, Bass S, Taylor AR, Ings RM, Campbell DB, Williams J (1992) Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. *Xenobiotica* 22: 1251-66, http://www.maps.org/publications/1992_marchant_1.pdf
- Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1996) Reinforcing effects of certain serotonin-releasing amphetamine derivatives. *Pharmacol Biochem Behav* 53: 99-105, http://www.maps.org/publications/1996_maronalewicka_1.pdf
- Marsh JC, Abboudi ZH, Gibson FM, Scopes J, Daly S, O'Shaunnessy DF, Baughan AS, Gordon-Smith EC (1994) Aplastic anaemia following exposure to 3,4-methylenedioxyamphetamine ('Ecstasy'). *Br J Haematol* 88: 281-5, http://www.maps.org/publications/1994_marsh_1.pdf
- Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. *Psychopharmacology (Berl)* 144: 67-76, http://www.maps.org/publications/1999_marston_1.pdf
- Martin DJ, Oren Z, Boone K (1991) Major depressives' and dysthmics' performance on the Wisconsin Card Sorting Test. *J Clin Psychol* 47: 684-90.,
- Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Portera L, Iqbal MI, Nock MK, Hartwell N (1998) Ambient temperature and mortality from unintentional cocaine overdose [see comments]. *Jama* 279: 1795-800,
- Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxyamphetamine in humans. *J Pharmacol Exp Ther* 290: 136-45, http://www.maps.org/publications/1999_mas_1.pdf
- Masters R, Houston J (1972) *Mind Games: The Guide to Inner Space*. Dell, Dell,
- Matsushima K, Nagai T, Kamiyama S (1998) Optical isomer analysis of 3,4-methylene-dioxyamphetamine analogues and their stereoselective disposition in rats. *J Anal Toxicol* 22: 33-9, http://www.maps.org/publications/1998_matsushima_1.pdf
- Matthai SM, Davidson DC, Sills JA, Alexandrou D (1996) Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water. *Bmj* 312: 1359, http://www.maps.org/publications/1996_matthai_1.pdf
- Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). *Toxicol Lett* 112-113: 133-42, http://www.maps.org/publications/2000_maurer_1.pdf
- Maxwell DL, Polkey MI, Henry JA (1993) Hyponatraemia and catatonic stupor after taking "ecstasy". *Bmj* 307: 1399, http://www.maps.org/publications/1993_maxwell_1.pdf
- McBean DE, Sharkey J, Ritchie IM, Kelly PA (1990) Evidence for a possible role for serotonergic systems in the control of cerebral blood flow. *Brain Res* 537: 307-10,
- McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999a) Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxyamphetamine (MDMA) users. *Psychopharmacology (Berl)* 147: 56-65, http://www.maps.org/publications/1999_mccann_1.pdf
- McCann UD, Eligulashvili V, Ricaurte GA (2000) (+/-)3,4-Methylenedioxyamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. *Neuropsychobiology* 42: 11-6, http://www.maps.org/publications/2000_mccann_1.pdf
- McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999b) Cognitive performance in (+/-) 3,4-methylenedioxyamphetamine (MDMA, "ecstasy") users: a controlled study. *Psychopharmacology (Berl)* 143: 417-25, http://www.maps.org/publications/1999_mccann_2.pdf
- McCann UD, Ricaurte G (2001) Caveat Emptor: Editors Beware. *Neuropsychopharmacology* 24: 333-334, http://www.maps.org/publications/2001_mccann_1.pdf
- McCann UD, Ricaurte GA (1991) Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons. *Brain Res* 545: 279-82, http://www.maps.org/publications/1991_mccann_2.pdf
- McCann UD, Ricaurte GA (1992) MDMA ("ecstasy") and panic disorder: induction by a single dose. *Biol Psychiatry* 32: 950-3, http://www.maps.org/publications/1992_mccann_1.pdf
- McCann UD, Ricaurte GA (1993) Reinforcing subjective effects of (+/-) 3,4-methylenedioxyamphetamine ("ecstasy") may be separable from its neurotoxic actions:

- clinical evidence. *J Clin Psychopharmacol* 13: 214-7,
http://www.maps.org/publications/1993_mccann_1.pdf
- McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. *Neuropsychopharmacology* 10: 129-38, http://www.maps.org/publications/1994_mccann_1.pdf
- McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. *Lancet* 352: 1433-7, http://www.maps.org/publications/1998_mccann_1.pdf
- McCreary AC, Bankson MG, Cunningham KA (1999) Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. *J Pharmacol Exp Ther* 290: 965-73, http://www.maps.org/publications/1999_mccreary_1.pdf
- McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999) Congenital anomalies after prenatal ecstasy exposure. *Lancet* 354: 1441-2, http://www.maps.org/publications/1999_mcelhatton_1.pdf
- McGuire PK, Cope H, Fahy TA (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). *Br J Psychiatry* 165: 391-5, http://www.maps.org/publications/1994_mcguire_1.pdf
- Mechan AO, O'Shea E, Elliott JM, Colado MI, Green AR (2001) A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. *Psychopharmacology (Berl)* on-line publication.
http://www.maps.org/publications/2001_mechan_1.pdf
- Meilman PW, Gaylor MS, Turco JH, Stone JE (1990) Drug use among college undergraduates: current use and 10-year trends. *Int J Addict* 25: 1025-36,
http://www.maps.org/publications/1990_meilman_1.pdf
- Melega WP, Lacan G, Harvey DC, Huang SC, Phelps ME (1998) Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [¹¹C]WIN 35,428 - positron emission tomography studies. *Neurosci Lett* 258: 17-20,
- Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF, 3rd (1998) Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging [see comments]. *Neuropsychopharmacology* 18: 407-30,
- Mendelson J, Jones RT, Upton R, Jacob P, 3rd (1995) Methamphetamine and ethanol interactions in humans. *Clin Pharmacol Ther* 57: 559-68,
- Mennini T, Fracasso C, Cagnotto A, Bergami A, Frittoli E, Gobbi M, Caccia S, Garattini S (1996) In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotonergic neuronal systems of non-human primates. A comparison with the rat. *Naunyn Schmiedebergs Arch Pharmacol* 353: 641-7,
- Metzger RR, Hanson GR, Gibb JW, Fleckenstein AE (1998) 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. *Eur J Pharmacol* 349: 205-10,
http://www.maps.org/publications/1998_metzger_1.pdf
- Miller DB, O'Callaghan JP (1993) The interactions of MK-801 with the amphetamine analogues D-methamphetamine (D-METH), 3,4-methylenedioxymethamphetamine (D-MDMA) or D-fenfluramine (D-FEN): neural damage and neural protection. *Ann N Y Acad Sci* 679: 321-4,
http://www.maps.org/publications/1993_miller_1.pdf
- Miller DB, O'Callaghan JP (1994) Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. *J Pharmacol Exp Ther* 270: 752-60, http://www.maps.org/publications/1994_miller_1.pdf
- Miller DB, O'Callaghan JP (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. *Mol Neurobiol* 11: 177-92, http://www.maps.org/publications/1995_miller_1.pdf
- Miller RT, Lau SS, Monks TJ (1996) Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyl-dopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. *Chem Res Toxicol* 9: 457-65,
http://www.maps.org/publications/1996_miller_1.pdf
- Miller RT, Lau SS, Monks TJ (1997) 2,5-Bis-(glutathion-S-yl)-alpha-methyl-dopamine, a putative metabolite of (+/-)-3,4-methylenedioxymethamphetamine, decreases brain serotonin concentrations. *Eur J Pharmacol* 323: 173-80, http://www.maps.org/publications/1997_miller_1.pdf

- Milosevic A, Agrawal N, Redfearn P, Mair L (1999) The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). *Community Dent Oral Epidemiol* 27: 283-7, http://www.maps.org/publications/1999_milosevic_1.pdf
- Milroy CM, Clark JC, Forrest AR (1996) Pathology of deaths associated with "ecstasy" and "eve" misuse. *J Clin Pathol* 49: 149-53, http://www.maps.org/publications/1996_milroy_1.pdf
- Mintzer S, Hickenbottom S, Gilman S (1999) Parkinsonism after taking ecstasy. *N Engl J Med* 340: 1443, http://www.maps.org/publications/1999_mintzer_1.pdf
- Moeller MR, Hartung M (1997) Ecstasy and related substances--serum levels in impaired drivers. *J Anal Toxicol* 21: 591, http://www.maps.org/publications/1997_moeller_1.pdf
- Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. *Ann N Y Acad Sci* 600: 649-61; discussion 661-4, http://www.maps.org/publications/1990_molliver_1.pdf
- Monks TJ, Ghersi-Egea JF, Philbert M, Cooper AJ, Lock EA (1999) Symposium overview: the role of glutathione in neuroprotection and neurotoxicity. *Toxicol Sci* 51: 161-77, http://www.maps.org/publications/1999_monks_1.pdf
- Moore KA, Mozayani A, Fierro MF, Poklis A (1996) Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. *Forensic Sci Int* 83: 111-9, http://www.maps.org/publications/1996_moore_1.pdf
- Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V (eds) *Toxicokinetics in new drug development*. Pergamon Press, New York, NY, pp 42-96,
- Morgan AE, Horan B, Dewey SL, Ashby CR, Jr. (1997) Repeated administration of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine in the nucleus accumbens: a microdialysis study. *Eur J Pharmacol* 331: R1-3, http://www.maps.org/publications/1997_morgan_1.pdf
- Morgan MJ (1998) Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. *Neuropsychopharmacology* 19: 252-64, http://www.maps.org/publications/1998_morgan_1.pdf
- Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). *Psychopharmacology (Berl)* 141: 30-6, http://www.maps.org/publications/1999_morgan_1.pdf
- Morland J (2000) Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. *Toxicol Lett* 112-113: 147-52, http://www.maps.org/publications/2000_morland_1.pdf
- Morrow BA, Roth RH (1996) Serotonergic lesions alter cocaine-induced locomotor behavior and stress-activation of the mesocorticolimbic dopamine system. *Synapse* 23: 174-181,
- Murray MO, Wilson NH (1998) Ecstasy related tooth wear. *Br Dent J* 185: 264, http://www.maps.org/publications/1998_murray_1.pdf
- Murray TK, Williams JL, Misra A, Colado MI, Green AR (1996) The spin trap reagent PBN attenuates degeneration of 5HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine. *Neuropharmacology* 35: 1615-20, http://www.maps.org/publications/1996_murray_1.pdf
- Myers RD (1975) Impairment of thermoregulation, food and water intakes in the rat after hypothalamic injections of 5,6-dihydroxytryptamine. *Brain Res* 94: 491-506,
- Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. *Life Sci* 47: 2401-8, http://www.maps.org/publications/1990_nash_1.pdf
- Nash JF, Brodtkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. *J Pharmacol Exp Ther* 259: 820-5, http://www.maps.org/publications/1991_nash_1.pdf
- Nash JF, Jr., Meltzer HY, Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 245: 873-9, http://www.maps.org/publications/1988_nash_1.pdf
- Nash JF, Nichols DE (1991) Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. *Eur J Pharmacol* 200: 53-8, http://www.maps.org/publications/1991_nash_2.pdf
- Nash JF, Roth BL, Brodtkin JD, Nichols DE, Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5HT_{2A} or 5HT_{2C} receptors. *Neurosci Lett* 177: 111-5, http://www.maps.org/publications/1994_nash_1.pdf

- Nash JF, Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. *Brain Res* 581: 237-43, http://www.maps.org/publications/1992_nash_1.pdf
- Nencini P, Woolverton WL, Seiden LS (1988) Enhancement of morphine-induced analgesia after repeated injections of methylenedioxymethamphetamine. *Brain Res* 457: 136-42, http://www.maps.org/publications/1988_nencini_1.pdf
- Netter P, Hennig J, Roed IS (1996) Serotonin and dopamine as mediators of sensation seeking behavior. *Neuropsychobiology* 34: 155-65,
- Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. *J Psychoactive Drugs* 18: 305-13, http://www.maps.org/publications/1986_nichols_1.pdf
- Nuvials X, Masclans JR, Peracaula R, de Latorre FJ (1997) Hyponatraemic coma after ecstasy ingestion. *Intensive Care Med* 23: 480, http://www.maps.org/publications/1997_nuvials_1.pdf
- Obradovic T, Imel KM, White SR (1998) Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin. *Brain Res* 785: 1-9, http://www.maps.org/publications/1998_obradovic_1.pdf
- Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T (1999) Ecstasy--long-term effects on the human central nervous system revealed by positron emission tomography. *Br J Psychiatry* 175: 186-8, http://www.maps.org/publications/1999_obrocki_1.pdf
- O'Cain PA, Hletko SB, Ogden BA, Varner KJ (2000) Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. *Physiol Behav* 70: 141-8, http://www.maps.org/publications/2000_ocain_1.pdf
- O'Callaghan J, Miller DB (in press) Neurotoxic effects of substituted amphetamines in rats and mice: challenges to the current dogma. In: Massaro E, Broderick PA (eds) *Handbook of Neurotoxicology*. Humana Press, New York, NY
- O'Callaghan JP, Jensen KF, Miller DB (1995) Quantitative aspects of drug and toxicant-induced astrogliosis. *Neurochem Int* 26: 115-24,
- O'Callaghan JP, Miller DB (1993) Quantification of reactive gliosis as an approach to neurotoxicity assessment. *NIDA Res Monogr* 136: 188-212, http://www.maps.org/publications/1993_ocallaghan_1.pdf
- O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. *J Pharmacol Exp Ther* 270: 741-51, http://www.maps.org/publications/1994_ocallaghan_1.pdf
- O'Connell D, Heffron JJ (2000) Rapid analysis of illicit drugs by mass spectrometry: results from seizures in Ireland. *Analyst* 125: 119-21, http://www.maps.org/publications/2000_oconnell_1.pdf
- O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B (1999) Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use. *N Z Med J* 112: 255-6, http://www.maps.org/publications/1999_oconnor_1.pdf
- O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. *J Neurosci* 8: 2788-803, http://www.maps.org/publications/1988_ohearn_1.pdf
- Olney JW (1994) New mechanisms of excitatory transmitter neurotoxicity. *J Neural Transm Suppl* 43: 47-51,
- O'Malley S, Adamse M, Heaton RK, Gawin FH (1992) Neuropsychological impairment in chronic cocaine abusers. *Am J Drug Alcohol Abuse* 18: 131-44,
- O'Neill D, Dart JK (1993) Methylenedioxyamphetamine ('Ecstasy') associated keratopathy. *Eye* 7: 805-6, http://www.maps.org/publications/1993_oneill_1.pdf
- Onwudike M (1996) Ecstasy induced retropharyngeal emphysema. *J Accid Emerg Med* 13: 359-61, http://www.maps.org/publications/1996_onwudike_1.pdf
- Ortuno J, Pizarro N, Farre M, Mas M, Segura J, Cami J, Brenneisen R, de la Torre R (1999) Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. *J Chromatogr B Biomed Sci Appl* 723: 221-32, http://www.maps.org/publications/1999_ortuno_1.pdf
- O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5HT nerve terminals and the dose and frequency of administration

- of MDMA ('ecstasy'). *Neuropharmacology* 37: 919-26,
http://www.maps.org/publications/1998_oshea_1.pdf
- Oswald I, Thacore VR (1963) Amphetamine and phenmetrazine addiction, physiological abnormalities in the abstinence syndrome. *British Medical Journal* 2: 427-431,
- Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Hernandez Lopez C, Ortuno J, Segura J, Cami J, de la Torre R (2000) Immunomodulating activity of MDMA. *Ann N Y Acad Sci* 914: 215-24, http://www.maps.org/publications/2000_pacifici_1.pdf
- Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. *Life Sci* 65: L309-16, http://www.maps.org/publications/1999_pacifici_1.pdf
- Pacifici R, Zuccaro P, Lopez CH, Pichini S, Di Carlo S, Farre M, Roset PN, Ortuno J, Segura J, Torre RL (2001) Acute effects of 3,4-methylenedioxyamphetamine alone and in combination with ethanol on the immune system in humans. *J Pharmacol Exp Ther* 296: 207-15,
http://www.maps.org/publications/2001_pacifici_1.pdf
- Parr MJ, Low HM, Botterill P (1997) Hyponatraemia and death after "ecstasy" ingestion. *Med J Aust* 166: 136-7, http://www.maps.org/publications/1997_parr_1.pdf
- Parrott AC (1998) The psychobiology of MDMA or 'ecstasy': symposium arranged by the Psychobiology Section, at the Annual Conference of the British Psychological Society, Heriot-Watt University, Edinburgh, April 1997. *J Psychopharmacol* 12: 97-102,
http://www.maps.org/publications/1998_parrott_3.pdf
- Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. *Psychopharmacology (Berl)* 139: 261-8,
http://www.maps.org/publications/1998_parrott_1.pdf
- Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. *J Psychopharmacol* 12: 79-83,
http://www.maps.org/publications/1998_parrott_2.pdf
- Parrott AC, Sisk E, Turner JJ (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. *Drug Alcohol Depend* 60: 105-10, http://www.maps.org/publications/2000_parrott_2.pdf
- Parrott AC, Stuart M (1997) Ecstasy (MDMA), amphetamine, and LSD: Comparative mood profiles in recreational polydrug users. *Human Psychopharmacology Clinical & Experimental* 12: 501-504,
http://www.maps.org/publications/1997_parrott_1.pdf
- Pedersen W, Skrandal A (1999) Ecstasy and new patterns of drug use: a normal population study. *Addiction* 94: 1695-706, http://www.maps.org/publications/1999_pedersen_1.pdf
- Perez JA, Arsuru EL, Strategos S (1999) Methamphetamine-related stroke: four cases. *J Emerg Med* 17: 469-71.,
- Peroutka SJ (1987) Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. *N Engl J Med* 317: 1542-3,
http://www.maps.org/publications/1987_peroutka_1.pdf
- Peroutka SJ (1989) 'Ecstasy': a human neurotoxin? *Arch Gen Psychiatry* 46: 191,
http://www.maps.org/publications/1989_johnson_1.pdf
- Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxyamphetamine in recreational users. *Neuropsychopharmacology* 1: 273-7,
http://www.maps.org/publications/1988_peroutka_1.pdf
- Peroutka SJ, Pascoe N, Faull KF (1987) Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxyamphetamine (MDMA; "Ecstasy"). *Research Comm in Subs Abuse* 8: 125-138, http://www.maps.org/publications/1987_peroutka_2.pdf
- Pittman JA, Pounsford JC (1997) Spontaneous pneumomediastinum and Ecstasy abuse. *J Accid Emerg Med* 14: 335-6, http://www.maps.org/publications/1997_pittman_1.pdf
- Plessinger MA (1998) Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. *Obstet Gynecol Clin North Am* 25: 119-38,
http://www.maps.org/publications/1998_plessinger_1.pdf
- Poblete JC, Azmitia EC (1995) Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxyamphetamine in astroglial-rich primary cultures: involvement of the 5HT_{2A} receptor. *Brain Res* 680: 9-15, http://www.maps.org/publications/1995_poblete_1.pdf
- Poklis A (1999) American Association for Clinical Chemistry/College of American Pathologists Urine Drug Testing (Screening) Survey Set UDS-C. Final Critique, 1999, Northfield IL

- Poland RE (1990) Diminished corticotropin and enhanced prolactin responses to 8-hydroxy-2(di-n-propylamino)tetralin in methylenedioxymethamphetamine pretreated rats. *Neuropharmacology* 29: 1099-101, http://www.maps.org/publications/1990_poland_1.pdf
- Poland RE, Lutchmansingh P, McCracken JT, Zhao JP, Brammer GL, Grob CS, Boone KB, Pechnick RN (1997) Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA. *Psychopharmacology (Berl)* 131: 411-9, http://www.maps.org/publications/1997_poland_1.pdf
- Pollock VE, Schneider LS (1990) Quantitative, waking EEG research on depression. *Biol Psychiatry* 27: 757-80,
- Pope HG, Jr., Yurgelun-Todd D (1996) The residual cognitive effects of heavy marijuana use in college students [see comments]. *Jama* 275: 521-7,
- Price LH, Ricaurte GA, Krystal JH, Heninger GR (1989) Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. *Arch Gen Psychiatry* 46: 20-2, http://www.maps.org/publications/1989_price_2.pdf
- Pu C, Broening HW, Vorhees CV (1996) Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. *Synapse* 23: 328-34, http://www.maps.org/publications/1996_pu_1.pdf
- Quin GI, McCarthy GM, Harries DK (1999) Spontaneous pneumomediastinum and ecstasy abuse. *J Accid Emerg Med* 16: 382, http://www.maps.org/publications/1999_quin_1.pdf
- Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD (1998) Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. *J Biol Chem* 273: 2458-66,
- Ramsey JD, Johnston A, Holt DW (1999) Death rate from use of ecstasy or heroin. *Lancet* 354: 2166, http://www.maps.org/publications/1999_ramsey_1.pdf
- Rashed AM, Anderson RA, King LA (2000) Solid-phase extraction for profiling of ecstasy tablets. *J Forensic Sci* 45: 413-7, http://www.maps.org/publications/2000_rashed_1.pdf
- Redfearn PJ, Agrawal N, Mair LH (1998) An association between the regular use of 3,4 methylenedioxy-methamphetamine (ecstasy) and excessive wear of the teeth. *Addiction* 93: 745-8, http://www.maps.org/publications/1998_redfearn_1.pdf
- Reed LJ, Winstock A, Cleare AJ, McGuire P (1999) Toxic effect of MDMA on brain serotonin neurons. *Lancet* 353: 1268; discussion 1270-1, http://www.maps.org/publications/1999_reed_1.pdf
- Reid LD, Hubbell CL, Tsai J, Fishkin MD, Amendola CA (1995) Naltrindole, a delta-opioid antagonist, blocks MDMA's ability to enhance pressing for rewarding brain stimulation. *Pharmacol Biochem Behav* 53: 477-80, http://www.maps.org/publications/1995_reid_1.pdf
- Rella JG, Nelson LS, Hoffman RS (2000) 7 years of 3,4-methylenedioxymethamphetamine (MDMA) toxicity. *Int J Med Toxicol* 3: 28,
- Reneman L, Booij J, Schmand B, van den Brink W, Gunning B (2000a) Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. *Psychopharmacology (Berl)* 148: 322-4, http://www.maps.org/publications/2000_reneman_2.pdf
- Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ (2000b) MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. *AJNR Am J Neuroradiol* 21: 1001-7, http://www.maps.org/publications/2000_reneman_1.pdf
- Renfroe CL (1986) MDMA on the street: Analysis Anonymous. *J Psychoactive Drugs* 18: 363-9, http://www.maps.org/publications/1986_renfroe_1.pdf
- Rezvani K, Kurbaan AS, Brenton D (1996) Ecstasy induced pneumomediastinum. *Thorax* 51: 960-1, http://www.maps.org/publications/1996_rezvani_1.pdf
- Ricaurte GA (1989) Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. *NIDA Res Monogr* 94: 306-22, http://www.maps.org/publications/1989_ricaurte_1.pdf
- Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988a) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. *Brain Res* 446: 165-8, http://www.maps.org/publications/1988_ricaurte_3.pdf
- Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW (1988b) 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. *Brain Res* 474: 359-63, http://www.maps.org/publications/1988_ricaurte_1.pdf

- Ricaurte GA, Finnegan KT, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. *Ann N Y Acad Sci* 600: 699-708; discussion 708-10, http://www.maps.org/publications/1990_ricaurte_1.pdf
- Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW (1988c) (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. *Jama* 260: 51-5, http://www.maps.org/publications/1988_ricaurte_3.pdf
- Ricaurte GA, Markowska AL, Wenk GL, Hatzidimitriou G, Wlos J, Olton DS (1993) 3,4-Methylenedioxymethamphetamine, serotonin and memory [published erratum appears in *J Pharmacol Exp Ther* 1994 Jan;268(1):529]. *J Pharmacol Exp Ther* 266: 1097-105, http://www.maps.org/publications/1993_ricaurte_1.pdf
- Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. *J Pharmacol Exp Ther* 261: 616-22, http://www.maps.org/publications/1992_ricaurte_2.pdf
- Ricaurte GA, McCann UD (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. *Ann N Y Acad Sci* 648: 371-82, http://www.maps.org/publications/1992_ricaurte_1.pdf
- Ricaurte GA, Yuan J, McCann UD (2000) (+/-)-3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. *Neuropsychobiology* 42: 5-10, http://www.maps.org/publications/2000_ricaurte_1.pdf
- Richards JR, Johnson EB, Stark RW, Derlet RW (1999) Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. *Am J Emerg Med* 17: 681-5.,
- Riedel WJ, Klaassen T, Deutz NE, van Someren A, van Praag HM (1999) Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. *Psychopharmacology (Berl)* 141: 362-9,
- Robinson TE, Camp DM (1987) Long-lasting effects of escalating doses of d-amphetamine on brain monoamines, amphetamine-induced stereotyped behavior and spontaneous nocturnal locomotion. *Pharmacol Biochem Behav* 26: 821-7,
- Robinson TE, Castaneda E, Whishaw IQ (1993) Effects of cortical serotonin depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. *Neuropsychopharmacology* 8: 77-85, http://www.maps.org/publications/1993_robinson_1.pdf
- Robson P, Bruce M (1997) A comparison of 'visible' and 'invisible' users of amphetamine, cocaine and heroin: two distinct populations? *Addiction* 92: 1729-36, http://www.maps.org/publications/1997_robson_1.pdf
- Rochester JA, Kirchner JT (1999) Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. *J Am Board Fam Pract* 12: 137-42, http://www.maps.org/publications/1999_rochester_1.pdf
- Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". *Psychopharmacology (Berl)* 151: 19-24, http://www.maps.org/publications/2000_rodgers_1.pdf
- Rohrig TP, Prouty RW (1992) Tissue distribution of methylenedioxymethamphetamine. *J Anal Toxicol* 16: 52-3, http://www.maps.org/publications/1992_rohrig_1.pdf
- Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse* 39: 32-41, http://www.maps.org/publications/2001_rothman_1.pdf
- Rothwell PM, Grant R (1993) Cerebral venous sinus thrombosis induced by 'ecstasy'. *J Neurol Neurosurg Psychiatry* 56: 1035, http://www.maps.org/publications/1993_rothwell_1.pdf
- Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. *Proc Natl Acad Sci U S A* 89: 1817-21, http://www.maps.org/publications/1992_rudnick_1.pdf
- Rush AJ, Weissenburger J, Vinson DB, Giles DE (1983) Neuropsychological dysfunctions in unipolar nonpsychotic major depressions. *J Affect Disord* 5: 281-7.,
- Ryan LJ, Linder JC, Martone ME, Groves PM (1990) Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. *Brain Res* 518: 67-77,

- Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS (1996) Methylendioxyamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. *J Pharmacol Exp Ther* 276: 846-54, http://www.maps.org/publications/1996_sabol_1.pdf
- Sabol KE, Seiden LS (1998) Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. *Brain Res* 806: 69-78, http://www.maps.org/publications/1998_sabol_1.pdf
- Saunders N, Doblin R (1996) Ecstasy: Dance, trance & transformation. Quick American Archives, Quick American Archives,
- Scallet AC, Lipe GW, Ali SF, Holson RR, Frith CH, Slikker W, Jr. (1988) Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylendioxyamphetamine. *Neurotoxicology* 9: 529-37, http://www.maps.org/publications/1988_scallet_1.pdf
- Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (+/-)3,4-(methylendioxy) methamphetamine injury: observations in rats. *J Pharmacol Exp Ther* 264: 1484-91, http://www.maps.org/publications/1993_scanzello_1.pdf
- Schechter MD (1991) Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. *Pharmacol Biochem Behav* 38: 539-44, http://www.maps.org/publications/1991_schechter_1.pdf
- Scheffel U, Lever JR, Stathis M, Ricaurte GA (1992) Repeated administration of MDMA causes transient down-regulation of serotonin 5HT₂ receptors. *Neuropharmacology* 31: 881-93, http://www.maps.org/publications/1992_scheffel_1.pdf
- Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain. *Synapse* 29: 183-92, http://www.maps.org/publications/1998_scheffel_1.pdf
- Schifano F (2000) Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. *Neuropsychobiology* 42: 25-33, http://www.maps.org/publications/2000_schifano_1.pdf
- Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. *Drug Alcohol Depend* 52: 85-90, http://www.maps.org/publications/1998_schifano_1.pdf
- Schifano F, Magni G (1994) MDMA ("ecstasy") abuse: psychopathological features and craving for chocolate: a case series. *Biol Psychiatry* 36: 763-7, http://www.maps.org/publications/1994_schifano_1.pdf
- Schirren CA, Berghaus TM, Sackmann M (1999) Thrombotic thrombocytopenic purpura after Ecstasy-induced acute liver failure. *Ann Intern Med* 130: 163, http://www.maps.org/publications/1999_schirren_1.pdf
- Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylendioxyamphetamine. *J Pharmacol Exp Ther* 240: 1-7, http://www.maps.org/publications/1987_schmidt_1.pdf
- Schmidt CJ, Abbate GM, Black CK, Taylor VL (1990a) Selective 5-hydroxytryptamine₂ receptor antagonists protect against the neurotoxicity of methylendioxyamphetamine in rats. *J Pharmacol Exp Ther* 255: 478-83, http://www.maps.org/publications/1990_schmidt_5.pdf
- Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990b) Methylendioxyamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5HT₂ receptors. *Brain Res* 529: 85-90, http://www.maps.org/publications/1990_schmidt_6.pdf
- Schmidt CJ, Black CK, Taylor VL (1990c) Antagonism of the neurotoxicity due to a single administration of methylendioxyamphetamine. *Eur J Pharmacol* 181: 59-70, http://www.maps.org/publications/1990_schmidt_4.pdf
- Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992a) The 5HT₂ receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylendioxyamphetamine. *Eur J Pharmacol* 220: 151-9, http://www.maps.org/publications/1992_schmidt_1.pdf
- Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (1992b) 5HT₂ receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue,

- 3,4-methylenedioxymethamphetamine. *Eur J Pharmacol* 223: 65-74,
http://www.maps.org/publications/1992_schmidt_2.pdf
- Schmidt CJ, Kehne JH (1990) Neurotoxicity of MDMA: neurochemical effects. *Ann N Y Acad Sci* 600: 665-80; discussion 680-1, http://www.maps.org/publications/1990_schmidt_1.pdf
- Schmidt CJ, Taylor VL (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. *Eur J Pharmacol* 156: 121-31,
http://www.maps.org/publications/1988_schmidt_1.pdf
- Schmidt CJ, Taylor VL (1990) Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5HT uptake inhibitors. *Eur J Pharmacol* 181: 133-6,
http://www.maps.org/publications/1990_schmidt_2.pdf
- Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR (1991) 5HT₂ antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. *J Pharmacol Exp Ther* 256: 230-5,
http://www.maps.org/publications/1991_schmidt_1.pdf
- Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. *Eur J Pharmacol* 124: 175-8,
http://www.maps.org/publications/1986_schmidt_1.pdf
- Schroeder B, Brieden S (2000) Bilateral sixth nerve palsy associated with MDMA ("ecstasy") abuse. *Am J Ophthalmol* 129: 408-9, http://www.maps.org/publications/2000_schroeder_1.pdf
- Schuster P, Lieb R, Lamertz C, Wittchen HU (1998) Is the use of ecstasy and hallucinogens increasing? Results from a community study. *Eur Addict Res* 4: 75-82,
http://www.maps.org/publications/1998_schuster_1.pdf
- Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU (1999) Fatal MDMA intoxication. *Lancet* 353: 593-4, http://www.maps.org/publications/1999_schwab_1.pdf
- Seiden LS, Woolverton WL, Lorens SA, Williams JE, Corwin RL, Hata N, Olinski M (1993) Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: the conflict between pharmacology and toxicology. *NIDA Res Monogr* 136: 34-46,
http://www.maps.org/publications/1993_seiden_1.pdf
- Selby MJ, Azrin RL (1998) Neuropsychological functioning in drug abusers. *Drug Alcohol Depend* 50: 39-45,
- Selmi F, Davies KG, Sharma RR, Neal JW (1995) Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. *Br J Neurosurg* 9: 93-6,
http://www.maps.org/publications/1995_selmi_1.pdf
- Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. *Br J Psychiatry* 175: 63-9,
http://www.maps.org/publications/1999_semple_1.pdf
- Series HG, Cowen PJ, Sharp T (1994) p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5HT in vivo. *Psychopharmacology (Berl)* 116: 508-14,
http://www.maps.org/publications/1994_series_1.pdf
- Sewell RA, Cozzi NV (1999) More about parkinsonism after taking ecstasy. *N Engl J Med* 341: 1400; discussion 1401, http://www.maps.org/publications/1999_sewell_1.pdf
- Shankaran M, Gudelsky GA (1998) Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. *Pharmacol Biochem Behav* 61: 361-6,
http://www.maps.org/publications/1998_shankaran_1.pdf
- Shankaran M, Gudelsky GA (1999) A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. *Psychopharmacology (Berl)* 147: 66-72, http://www.maps.org/publications/1999_shankaran_1.pdf
- Shankaran M, Yamamoto B, Gudelsky G (2001) Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5HT. *Synapse* 40: 55-64.,
http://www.maps.org/publications/2001_shankaran_1.pdf
- Shankaran M, Yamamoto BK, Gudelsky GA (1999a) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. *Eur J Pharmacol* 385: 103-10, http://www.maps.org/publications/1999_shankaran_2.pdf

- Shankaran M, Yamamoto BK, Gudelsky GA (1999b) Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. *J Neurochem* 72: 2516-22, http://www.maps.org/publications/1999_shankaran_3.pdf
- Shapiro Y, Magazanik A, Udassin R, Ben-Baruch G, Shvartz E, Shoenfeld Y (1979) Heat intolerance in former heatstroke patients. *Ann Intern Med* 90: 913-6,
- Sharkey J, McBean DE, Kelly PA (1991) Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxyamphetamine ("Ecstasy"). *Psychopharmacology (Berl)* 105: 113-8, http://www.maps.org/publications/1991_sharkey_1.pdf
- Sharma R, Nelson LS (2000) Methylenedioxyamphetamine (MDMA) induced hyponatremia. *Int J Med Toxicol* 3: 29,
- Shearman JD, Chapman RW, Satsangi J, Ryley NG, Weatherhead S (1992) Misuse of ecstasy. *Bmj* 305: 309, http://www.maps.org/publications/1992_shearman_1.pdf
- Sherlock K, Wolff K, Hay AW, Conner M (1999) Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. *J Accid Emerg Med* 16: 194-7, http://www.maps.org/publications/1999_sherlock_1.pdf
- Shewan D, Dalgarno P (1996) Ecstasy and neurodegeneration. ...such as ketamine. *Bmj* 313: 424, http://www.maps.org/publications/1996_shewan_1.pdf
- Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds) *The Pharmacology of Hallucinogens*. Pergamon, New York. http://www.maps.org/publications/1978_shulgin_1.pdf
- Siegel RK (1986) MDMA. Nonmedical use and intoxication. *J Psychoactive Drugs* 18: 349-54, http://www.maps.org/publications/1986_siegel_1.pdf
- Simantov R, Tauber M (1997) The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. *Faseb J* 11: 141-6, http://www.maps.org/publications/1997_simantov_1.pdf
- Simpson DL, Rumack BH (1981) Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. *Arch Intern Med* 141: 1507-9., http://www.maps.org/publications/1981_simpson_1.pdf
- Singarajah C, Lavies NG (1992) An overdose of ecstasy. A role for dantrolene. *Anaesthesia* 47: 686-7, http://www.maps.org/publications/1992_singarajah_1.pdf
- Slikker W, Jr., Ali SF, Scallet AC, Frith CH, Newport GD, Bailey JR (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxyamphetamine (MDMA). *Toxicol Appl Pharmacol* 94: 448-57, http://www.maps.org/publications/1988_slikker_1.pdf
- Slikker W, Jr., Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. *Neurotoxicology* 10: 529-42, http://www.maps.org/publications/1989_slikker_1.pdf
- Slotkin TA, Seidler FJ, Ali SF (2000) Cellular determinants of reduced adaptability of the aging brain: neurotransmitter utilization and cell signaling responses after MDMA lesions. *Brain Res* 879: 163-173, http://www.maps.org/publications/2000_slotkin_1.pdf
- Smilkstein MJ, Smolinske SC, Rumack BH (1987) A case of MAO inhibitor/MDMA interaction: agony after ecstasy. *J Toxicol Clin Toxicol* 25: 149-59, http://www.maps.org/publications/1987_smilkstein_1.pdf
- Smit AA, Wieling W, Voogel AJ, Koster RW, van Zwieten PA (1996) Orthostatic hypotension due to suppression of vasomotor outflow after amphetamine intoxication. *Mayo Clin Proc* 71: 1067-70, http://www.maps.org/publications/1996_smit_1.pdf
- Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of 'Ecstasy' users and their experiences with the drug. *Br J Addict* 87: 1161-72, http://www.maps.org/publications/1992_solowij_1.pdf
- Sondermann N, Kovar KA (1999) Screening experiments of ecstasy street samples using near infrared spectroscopy. *Forensic Sci Int* 106: 147-56, http://www.maps.org/publications/1999_sondermann_1.pdf
- Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxyamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat [published erratum appears in

- Pharmacol Biochem Behav 1989 Nov;34(3):679]. Pharmacol Biochem Behav 32: 835-40,
http://www.maps.org/publications/1989_spanos_1.pdf
- Spatt J, Glawar B, Mamoli B (1997) A pure amnesic syndrome after MDMA ("ecstasy") ingestion. J Neurol Neurosurg Psychiatry 62: 418-9, http://www.maps.org/publications/1997_spatt_1.pdf
- Speedy DB, Noakes TD, Rogers IR, Thompson JM, Campbell RG, Kuttner JA, Boswell DR, Wright S, Hamlin M (1999) Hyponatremia in ultradistance triathletes. Med Sci Sports Exerc 31: 809-15,
- Spoont MR (1992) Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 112: 330-50.,
- Sprague JE, Huang X, Kanthasamy A, Nichols DE (1994) Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci 55: 1193-8,
http://www.maps.org/publications/1994_sprague_1.pdf
- Sprague JE, Nichols DE (1995a) Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology (Berl) 118: 357-9,
http://www.maps.org/publications/1995_sprague_2.pdf
- Sprague JE, Nichols DE (1995b) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273: 667-73, http://www.maps.org/publications/1995_sprague_1.pdf
- Sprague JE, Worst T, Kanthasamy A, Nichols DE, Kane MD (1999) Effects of antisense oligonucleotide alteration of MAO-B gene expression on MDMA-induced serotonergic neurotoxicity Society for Neuroscience, Miami, FL, pp Abs. 836.19, http://www.maps.org/publications/1999_sprague_1.pdf
- Squier MV, Jalloh S, Hilton-Jones D, Series H (1995) Death after ecstasy ingestion: neuropathological findings. J Neurol Neurosurg Psychiatry 58: 756,
http://www.maps.org/publications/1995_squier_1.pdf
- Sreenivasan VR (1972) Problems in identification of methylenedioxy and methoxy amphetamines. Journal of Criminal Law, Criminology & Police Science 63: 304-312,
- St Omer VE, Ali SF, Holson RR, Duhart HM, Scalzo FM, Slikker W, Jr. (1991) Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol Teratol 13: 13-20, http://www.maps.org/publications/1991_stomer_1.pdf
- Steele TD, Brewster WK, Johnson MP, Nichols DE, Yim GK (1991) Assessment of the role of alpha-methylepine in the neurotoxicity of MDMA. Pharmacol Biochem Behav 38: 345-51,
http://www.maps.org/publications/1991_steele_1.pdf
- Stein DJ, Rink J (1999) Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. J Clin Psychiatry 60: 485, http://www.maps.org/publications/1999_stein_1.pdf
- Stern RA, Silva SG, Chaisson N, Evans DL (1996) Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol 53: 148-53,
- Stone DM, Hanson GR, Gibb JW (1987a) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26: 1657-61,
http://www.maps.org/publications/1987_stone_1.pdf
- Stone DM, Hanson GR, Gibb JW (1989a) In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J Neurochem 53: 572-81,
http://www.maps.org/publications/1989_stone_2.pdf
- Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247: 79-87, http://www.maps.org/publications/1988_stone_1.pdf
- Stone DM, Johnson M, Hanson GR, Gibb JW (1989b) Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol 172: 93-7,
http://www.maps.org/publications/1989_stone_1.pdf
- Stone DM, Merchant KM, Hanson GR, Gibb JW (1987b) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26: 1677-83, http://www.maps.org/publications/1987_stone_2.pdf
- Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128: 41-8, http://www.maps.org/publications/1986_stone_1.pdf
- Stone RJ (1993) Treatment of 'ecstasy' overdose with dantrolene. Anaesthesia 48: 83,
http://www.maps.org/publications/1993_stone_1.pdf

- Stuart R (2000) MDMA Psychotherapy: An Annotated Bibliography of Late 20th Century English-language Literature. Graduate School of Professional Psychology. John F. Kennedy University, Orinda, CA
- Stumm G, Schlegel J, Schafer T, Wurz C, Mennel HD, Krieg JC, Vedder H (1999) Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. *FASEB J* 13: 1065-72, http://www.maps.org/publications/1999_stumm_1.pdf
- Suarez RV, Riemersma R (1988) "Ecstasy" and sudden cardiac death. *Am J Forensic Med Pathol* 9: 339-41, http://www.maps.org/publications/1988_suarez_1.pdf
- Sultana SR, Byrne DJ (1996) 'Raver's' haematuria. *J R Coll Surg Edinb* 41: 419-20, http://www.maps.org/publications/1996_sultana_1.pdf
- Taffe MA, Weed MR, Davis S, Salvador Huitrón-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, Gold LH (2001) Functional Consequences of Repeated (\pm)3,4-Methylenedioxymethamphetamine (MDMA) Treatment in Rhesus Monkeys. *Neuropsychopharmacology* 24: 230-239, http://www.maps.org/publications/2001_taffe_1.pdf
- Tagaya M, Liu KF, Copeland B, Seiffert D, Engler R, Garcia JH, del Zoppo GJ (1997) DNA scission after focal brain ischemia. Temporal differences in two species. *Stroke* 28: 1245-54,
- Taraska T, Finnegan KT (1997) Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 280: 941-7, http://www.maps.org/publications/1997_taraska_1.pdf
- Tehan B (1993) Ecstasy and dantrolene. *Bmj* 306: 146, http://www.maps.org/publications/1993_tehan_2.pdf
- Tehan B, Hardern R, Bodenham A (1993) Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'). *Anaesthesia* 48: 507-10, http://www.maps.org/publications/1993_tehan_1.pdf
- Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. *Drug Alcohol Depend* 55: 105-15, http://www.maps.org/publications/1999_topp_1.pdf
- Tuchenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E (2000) High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. *Neuropsychopharmacology* 22: 608-17, http://www.maps.org/publications/2000_tuchenhagen_1.pdf
- Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). *Biochem Pharmacol* 47: 1151-6, http://www.maps.org/publications/1994_tucker_1.pdf
- Turner JJ, Parrott AC (2000) 'Is MDMA a human neurotoxin?': diverse views from the discussants. *Neuropsychobiology* 42: 42-8, http://www.maps.org/publications/2000_turner_1.pdf
- Uhlenhuth EH, Johanson CE, Kilgore K, Kobasa SC (1981) Drug preference and mood in humans: preference for d-amphetamine and subject characteristics. *Psychopharmacology* 74: 191-4,
- van de Wijngaart GF, Braam R, de Bruin D, Fris M, Maalste NJM, Verbraeck HT (1999) Ecstasy use at large-scale dance events in the Netherlands. *Journal of Drug Issues* 29: 679-702, http://www.maps.org/publications/1999_vandewijngaart_1.pdf
- van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin RM, Innis RB (2000) Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. *Neurobiol Aging* 21: 497-501,
- van Tonningen-van Driel MM, Garbis-Berkvens JM, Reuvers-Lodewijks WE (1999) [Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)]. *Ned Tijdschr Geneesk* 143: 27-31.,
- Vander Borgh T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. *Eur J Pharmacol* 294: 577-83,
- Varela-Rey M, Montiel-Duarte C, Beitia G, Cenarruzabeitia E, Iraburu MJ (1999) 3,4-methylenedioxymethamphetamine ("Ecstasy") stimulates the expression of alpha1(I) procollagen mRNA in hepatic stellate cells. *Biochem Biophys Res Commun* 259: 678-82, http://www.maps.org/publications/1999_varelarey_1.pdf

- Vargas-Rivera J, Ortega-Corona BG, Garcia-Pineda J, Carranza J, Salazar LA, Villarreal J (1990) Influence of previous housing history on the toxicity of amphetamine in aggregate mice. *Arch Invest Med (Mex)* 21: 65-9.
- Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin E, Van de Wijngaart G, Van Gerven JMA, Cohen AF (2001) Cognitive performance and serotonergic function in users of ecstasy. *Psychopharmacology (Berl)* 153: 196-202, http://www.maps.org/publications/2001_verkes_1.pdf
- Viriden TB, Baker LE (1999) Disruption of the discriminative stimulus effects of S(+)-3,4-methylenedioxymethamphetamine (MDMA) by (+/-)-MDMA neurotoxicity: protection by fluoxetine. *Behav Pharmacol* 10: 195-204, http://www.maps.org/publications/1999_viriden_1.pdf
- Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K (1988) Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. *Br J Psychiatry* 152: 641-8,
- Vollenweider FX, Gamma A, Liechti M, Huber T (1998a) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. *Neuropsychopharmacology* 19: 241-51, http://www.maps.org/publications/1998_vollenweider_1.pdf
- Vollenweider FX, Gamma A, Liechti M, Huber T (1999a) Is a single dose of MDMA harmless? *Neuropsychopharmacology* 21: 598-600, http://www.maps.org/publications/1999_vollenweider_1.pdf
- Vollenweider FX, Jones RT, Baggott MJ (2001) Caveat emptor: Editors beware. *Neuropsychopharmacology* 24: 461-463, http://www.maps.org/publications/2001_vollenweider_1.pdf
- Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999b) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. *Psychopharmacology (Berl)* 143: 365-72, http://www.maps.org/publications/1999_vollenweider_2.pdf
- Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998b) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* 9: 3897-902,
- Vorhees CV (1997) Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins. *Drug and Chemical Toxicology* 20: 387-99, http://www.maps.org/publications/1997_vorhees_1.pdf
- Wallace TL, Gudelsky GA, Vorhees CV (2001) Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. *Psychopharmacology (Berl)* 153: 321-6., http://www.maps.org/publications/2001_wallace_1.pdf
- Walubo A, Seger D (1999) Fatal multi-organ failure after suicidal overdose with MDMA, 'ecstasy': case report and review of the literature. *Hum Exp Toxicol* 18: 119-25, http://www.maps.org/publications/1999_walubo_1.pdf
- Wareing M, Fisk JE, Murphy PN (2000) Working memory deficits in current and previous users of MDMA ('ecstasy'). *Br J Psychol* 91: 181-8, http://www.maps.org/publications/2000_wareing_1.pdf
- Watson ID, Serlin M, Moncur P, Tames F (1997) Acute hyponatraemia. *Postgrad Med J* 73: 443-4, http://www.maps.org/publications/1997_watson_1.pdf
- Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH (1993) Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? *Anaesthesia* 48: 1057-60, http://www.maps.org/publications/1993_watson_1.pdf
- Watson L, Beck J (1991) New age seekers: MDMA use as an adjunct to spiritual pursuit. *J Psychoactive Drugs* 23: 261-70, http://www.maps.org/publications/1991_watson_1.pdf
- Watson R, Hartmann E, Schildkraut JJ (1972) Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. *Am J Psychiatry* 129: 263-9.,
- Webb C, Williams V (1993) Ecstasy intoxication: appreciation of complications and the role of dantrolene. *Anaesthesia* 48: 542-3, http://www.maps.org/publications/1993_webb_1.pdf
- Webb E, Ashton CH, Kelly P, Kamah F (1998) An update on British medical students' lifestyles. *Med Educ* 32: 325-31, http://www.maps.org/publications/1998_webb_1.pdf
- Webb E, Ashton CH, Kelly P, Kamali F (1996) Alcohol and drug use in UK university students. *Lancet* 348: 922-5, http://www.maps.org/publications/1996_webb_1.pdf

- Whitaker-Azmitia PM, Aronson TA (1989) "Ecstasy" (MDMA)-induced panic. *Am J Psychiatry* 146: 119, http://www.maps.org/publications/1989_whitakerazmitia_1.pdf
- White JM, Bochner F, Irvine RJ (1997) The agony of "ecstasy". *Med J Aust* 166: 117-8, http://www.maps.org/publications/1997_white_1.pdf
- Widmer S (1997) Listening into the heart of things: The awakening of love: On MDMA and LSD: The undesired psychotherapy. Basic Editions, Basic Editions,
- Wilkerson G, London ED (1989) Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. *Neuropharmacology* 28: 1129-38, http://www.maps.org/publications/1989_wilkerson_1.pdf
- Wilkins B (1996) Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input. *Bmj* 313: 689-90; discussion 690, http://www.maps.org/publications/1996_wilkins_1.pdf
- Williams A, Segal O, Andrews B (1998a) Short gastric artery perforation after use of 'ecstasy'. *J R Soc Med* 91: 541-2, http://www.maps.org/publications/1998_williams_2.pdf
- Williams A, Unwin R (1997) Prolonged elevation of serum creatine kinase (CK) without renal failure after ingestion of ecstasy. *Nephrol Dial Transplant* 12: 361-2, http://www.maps.org/publications/1997_williams_1.pdf
- Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A (1998b) "Saturday night fever": ecstasy related problems in a London accident and emergency department. *J Accid Emerg Med* 15: 322-6, http://www.maps.org/publications/1998_williams_1.pdf
- Williams JH, Azmitia EC (1981) Hippocampal serotonin re-uptake and nocturnal locomotor activity after microinjections of 5,7-DHT in the fornix-fimbria. *Brain Res* 207: 95-107,
- Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J (1997) Adverse effects of stimulant drugs in a community sample of drug users. *Drug Alcohol Depend* 44: 87-94, http://www.maps.org/publications/1997_williamson_1.pdf
- Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. *Nat Med* 2: 699-703,
- Wilson MA, Molliver ME (1994) Microglial response to degeneration of serotonergic axon terminals. *Glia* 11: 18-34,
- Wilson MA, Ricaurte GA, Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. *Neuroscience* 28: 121-37, http://www.maps.org/publications/1989_wilson_1.pdf
- Windhaber J, Maierhofer D, Dantendorfer K (1998) Panic disorder induced by large doses of 3,4-methylenedioxymethamphetamine resolved by paroxetine. *J Clin Psychopharmacol* 18: 95-6, http://www.maps.org/publications/1998_windhaber_1.pdf
- Winslow JT, Insel TR (1990) Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. *J Pharmacol Exp Ther* 254: 212-20, http://www.maps.org/publications/1990_winslow_1.pdf
- Winstock AR, King LA (1996) Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy... *BMJ* 313: 423-4, http://www.maps.org/publications/1996_winstock_1.pdf
- Wolff K, Hay AW, Sherlock K, Conner M (1995) Contents of "ecstasy". *Lancet* 346: 1100-1, http://www.maps.org/publications/1995_wolff_1.pdf
- Wolfson PE (1985) Testimony of Philip E. Wolfson, M.D. In the Matter of MDMA Scheduling. Docket No. 84-48. (United States Department of Justice, Drug Enforcement Administration.)
- Wolfson PE (1986) Meetings at the edge with Adam: A man for all seasons? *Journal of Psychoactive Drugs* 18: 329-333, http://www.maps.org/publications/1986_wolfson_1.pdf
- Wollina U, Kammler HJ, Hesselbarth N, Mock B, Bosseckert H (1998) Ecstasy pimples - a new facial dermatosis. *Dermatology* 197: 171-3, http://www.maps.org/publications/1998_wollina_1.pdf
- Woodrow G, Harnden P, Turney JH (1995) Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine ('ecstasy'). *Nephrol Dial Transplant* 10: 399-400, http://www.maps.org/publications/1995_woodrow_1.pdf
- Wright JD, Pearl L (1990) Knowledge and experience of young people regarding drug abuse, 1969-89. *Bmj* 300: 99-103, http://www.maps.org/publications/1990_wright_1.pdf

- Wright JD, Pearl L (1995) Knowledge and experience of young people regarding drug misuse, 1969-94 [published erratum appears in *BMJ* 1995 Jan 21;310(6973):164]. *Bmj* 310: 20-4, http://www.maps.org/publications/1995_wright_1.pdf
- Wright JD, Pearl L (2000) Experience and knowledge of young people regarding illicit drug use, 1969-99. *Addiction* 95: 1225-35, http://www.maps.org/publications/2000_wright_1.pdf
- Wrona MZ, Dryhurst G (1998) Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. *Chem Res Toxicol* 11: 639-50,
- Wu C, Singh SK, Dias P, Kumar S, Mann DM (1999) Activated astrocytes display increased 5HT_{2A} receptor expression in pathological states. *Exp Neurol* 158: 529-33,
- Wu D, Otton SV, Inaba T, Kalow W, Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. *Biochem Pharmacol* 53: 1605-12, http://www.maps.org/publications/1997_wu_1.pdf
- Yang Z, Wrona MZ, Dryhurst G (1997) 5-hydroxy-3-ethylamino-2-oxindole is not formed in rat brain following a neurotoxic dose of methamphetamine: evidence that methamphetamine does not induce the hydroxyl radical-mediated oxidation of serotonin. *J Neurochem* 68: 1929-41,
- Yeh SY (1997) Effects of salicylate on 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. *Pharmacol Biochem Behav* 58: 701-8, http://www.maps.org/publications/1997_yeh_1.pdf
- Yeh SY (1999) N-tert-butyl-alpha-phenylnitronone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. *Synapse* 31: 169-77, http://www.maps.org/publications/1999_yeh_1.pdf
- Yeh SY, Dersch C, Rothman R, Cadet JL (1999) Effects of antihistamines on 3, 4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. *Synapse* 33: 207-17, http://www.maps.org/publications/1999_yeh_2.pdf
- Yousif MY, Fitzgerald RL, Narasimhachari N, Rosecrans JA, Blanke RV, Glennon RA (1990) Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. *Drug Alcohol Depend* 26: 127-35, http://www.maps.org/publications/1990_yousif_1.pdf
- Zakzanis KK, Young DA (2001) Memory impairment in abstinent MDMA ("Ecstasy") users: A longitudinal investigation. *Neurology* 56: 966-9., http://www.maps.org/publications/2001_zakzanis_1.pdf
- Zenenberg R, Goldfarb DS (2000) Evaluation of hyponatremia associated with the use of methylenedioxymethamphetamine (MDMA). *Int J Med Toxicol* 3: 30,
- Zhao ZY, Castagnoli N, Jr., Ricaurte GA, Steele T, Martello M (1992) Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. *Chem Res Toxicol* 5: 89-94, http://www.maps.org/publications/1992_zhao_1.pdf
- Zheng Y, Laverty R (1998) Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. *Brain Res* 795: 257-63, http://www.maps.org/publications/1998_zheng_1.pdf
- Zuckerman M (1996) The psychobiological model for impulsive unsocialized sensation seeking: a comparative approach. *Neuropsychobiology* 34: 125-9,